CA2410023C - Coated nanoparticles - Google Patents
Coated nanoparticles Download PDFInfo
- Publication number
- CA2410023C CA2410023C CA2410023A CA2410023A CA2410023C CA 2410023 C CA2410023 C CA 2410023C CA 2410023 A CA2410023 A CA 2410023A CA 2410023 A CA2410023 A CA 2410023A CA 2410023 C CA2410023 C CA 2410023C
- Authority
- CA
- Canada
- Prior art keywords
- nanoparticles
- functional group
- core
- silica
- mean size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
- B01J13/18—In situ polymerisation with all reactants being present in the same phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0001—Post-treatment of organic pigments or dyes
- C09B67/0004—Coated particulate pigments or dyes
- C09B67/0005—Coated particulate pigments or dyes the pigments being nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/552—Glass or silica
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2446/00—Magnetic particle immunoreagent carriers
- G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2993—Silicic or refractory material containing [e.g., tungsten oxide, glass, cement, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2993—Silicic or refractory material containing [e.g., tungsten oxide, glass, cement, etc.]
- Y10T428/2995—Silane, siloxane or silicone coating
Abstract
Disclosed are silica-coated nanoparticles and a process for producing silica-coated nanoparticles. Silica-nanoparticles are prepared by precipitating nano-sized cores from reagents dissolved in the aqueous compartment of a water-in-oil microemulsion. A reactive silicate is added to coat the cores with silica.
Also disclosed are methods for functionalizing silica-coated nanoparticles for use in a variety of applications.
Also disclosed are methods for functionalizing silica-coated nanoparticles for use in a variety of applications.
Description
COATED NANOPARTICLES
Statement As To Federally Sponsored Research This invention was made with U.S. government support under grant number N00014-98-1-0621 awarded by the Office of Naval Research and grant number NSF
BIO-9871880 awarded by the National Science Foundation. The U.S. government may have certain rigllts in the invention.
Field Of The Invention The invention relates generally to the field of nanoparticles and methods of making nanoparticles. More particularly, the invention relates to silica-coated nanoparticles prepared by using microeinulsions.
Background Of The Invention Nanoparticles are veiy small particles typically ranging in size from as small as one nanometer to as large as several hundred nanometers in diameter. Their small size allows nanoparticles to be exploited to produce a variety of products such as dyes and pigments;
aesthetic or functional coatings; tools for biological discovery, medical imaging, and therapeutics; magnetic recording media; quantum dots; and even uniforin and nanosize semiconductors.
Nanoparticles can be simple aggregations of molecules or they can be structured into two or more layers of different substances. For exainple, simple nanoparticles consisting of magnetite or maghemite can be used in magnetic applications (e.g., MRI
contrast agents, cell separation tools, or data storage). See, e.g., Scientific and Clinical Applications of Ma ng etic Microspheres, U.Hafeli, W. Schutt, J. Teller, and M.Zborowski (eds.) Plenum Press, New York, 1997; Sjogren et al., Magn.Reson. Med. 31: 268, 1994; and Tiefenauer et al., Bioconjugate Chem. 4:347, 1993. More complex nanoparticles can consist of a core made of one substance and a shell made of another.
Many different type of small particles (nanoparticles or micron-sized particles) are commercially available from several different manufacturers including: Bangs Laboratories (Fishers, Indiana); Promega (Madison, WI); Dynal Inc.(Lake Success, New York);
Advanced Magnetics Inc.(Surrey, U.K.); CPG Inc.(Lincoln Park, New Jersey); Cortex Biochem (San Leandro, California); European Institute of Science (Lund, Sweden);
Ferrofluidics Corp.
(Nashua, New Hampshire); FeRx Inc.; (San Diego, California); Immunicon Corp.;
(Huntingdon Valley, Pennsylvania); Magnetically Delivered Therapeutics Inc.
(San Diego, CA); Miltenyi Biotec GmbH (USA); Microcaps GmbH (Rostock, Germany);
PolyMicrospheres Inc. (Indianapolis, IN); Scigen Ltd.(Kent, U.K.); Seradyn Inc.;
(Indianapolis, Indiana); and Spherotech Inc. (Libertyville, Illinois). Most of these particles are made using conventional techniques, such as grinding and milling, emulsion polymerization, block copolymerization, and microemulsion.
Methods of making silica nanoparticles have also been reported. The processes involve crystallite core aggregation (Philipse et al., Langmuir, 10:92, 1994);
fortification of superparamagnetic polymer nanoparticles with intercalated silica (Gruttner, C
and J Teller, Journal of Magnetism and Magnetic Materials, 194:8, 1999); and microwave-mediated self-assembly (Correa-Duarte et al., Langmuir, 14:6430, 1998). Unfortunately, these techniques have not proven to be particularly efficient for consistently fabricating nanoparticles with a particular size, shape and size distribution.
Summary Of The Invention The invention relates to a new method for preparing nanoparticles having a core enveloped by a silica (SiOZ) shell.. Such silica-coated nanoparticles can be used, for example, as dye-doped particles, "pigmentless" pigment particles, metal particles, semiconductor particles, magnetic particles, and drug molecule particles The method employs a microemulsion, i.e., isotropic and thermodynamically stable single-phase system, to produce nanoparticles cores of a predetermined, very uniform size and shape. Cores produced using the microemuslion are then coated with silica using a silicating agent. The nanoparticles thus formed can be customized for a particular application by derivatizing various chemical groups onto the silica coating.
Accordingly, the invention features nanoparticles having a core and a silica shell enveloping the core. The nanoparticles can have a mean size of less than 1 micron (e.g., between 1 nm and 300 nm, or between 2 nm and 10 nm). In some variations, the nanoparticle cores can be magnetic and can include a metal selected from the group consisting of magnetite, maghemite, and greigite. In other variations, the core includes a pigment which can be an inorganic salt such as potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, or copper nitrate. Similarly, the core can include a dye such as Ru/Bpy, Eu/Bpy, or the like; or a metal such as Ag and Cd.
The invention also features nanoparticles with a silica shell that is derivatized with a functional group such as a protein (e.g., an antibody); a nucleic acid (e.g., an oligonucleotide);
biotin; or streptavidin.
Also within the invention is a method of making coated nanoparticles. This method includes the steps of: providing a microemulsion; providing a first aqueous solution of a first reactant and a second aqueous solution of a second reactant (the first reactant and second reactant being selected such that a solid precipitate forms upon mixing the first and second reactants together in an aqueous environment); adding the first aqueous solution to a first aliquot of the microemulsion and the second aqueous solution to a second aliquot of the microemulsion; mixing together the first and second aliquots to form a reaction mixture that reacts to form nanoparticle cores; and adding a coating agent to the cores to form coated nanoparticles.
The microemulsion can be a water-in-oil microeinulsion that can be made by mixing togetller water; a relatively polar liquid such as isooctane, n-hexane, or cyclohexane; a surfactant such as AOT, TX-100, and CTAB; and, in some cases, a cosurfactant such as n-hexanol. The coating agent can be a reactive silicate such as TEOS and APTS.
In some variations, the method includes a step of derivatizing the silica shell with a functional group such as a protein (e.g., an antibody); a nucleic acid (e.g., an oligonucleotide); biotin; or streptavidin. Thus, the method of the invention can be used to malce protein-derivatized, silica-coated nanoparticles having cores including a metal such as magnetite, maglleinite, or greigite.
In another aspect, the invention features a method of identifying cells expressing a preselected molecule. This method includes the steps of: providing a plurality of silica-coated nanoparticles coated with a functional group that binds to a preselected molecule;
providing a plurality of cells at least some of which express the preselected molecule; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture;
placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles. In one variation of this method, the functional group is an antibody that specifically binds to the preselected _ SECTIO!q 8 Cf~P~4~'CT*._-.
I~
S~_ r~`..-6~9z,~ ATg ~ . ~;.
CORi:, LEg V~- '. :: .. . ,+.i CA'1=
molecule. In another variation, the silica-coated nanoparticles are fluorescent.
As used herein, the word "nanoparticle" means a particle having a diameter of between about 1 and 1000 nm. Similarly, by the term "nanoparticles" is meant a plurality of particles having an average diameter of between about 1 and 1000 nm.
For the purposes herein, a microemulsion is defined as a thermodynamically stable, optically isotropic dispersion of two inuniscible liquids consisting of nanosize domains of one or both liquids in the other, stabilized by an interfacial film of surface-active molecules.
By reference to the "size" of a nanoparticle is meant the length of the largest straight dimension of the nanoparticle. For example, the size of a perfectly spherical nanoparticle is its diameter.
By the phrase "specifically binds" means that one molecule recognizes and adheres to a particular second molecule in a sample, but does not substantially recognize or adhere to other molecules in the sample. Generally, an antibody that "specifically binds" a preselected antigen is one that binds the antigen with a binding affinity greater than about 105 to 106 liters/mole.
As used herein, the phrase "functional group" means a chemical group that imparts a particular function to an article (e.g., nanoparticle) bearing the chemical group. For example, functional groups can include substances such as antibodies, oligonucleotides, biotin, or streptavidin that are known to bind particular molecules; or small chemical groups such as amines, carboxylates, and the like.
Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In the case of conflict, the present specification, including definitions will control. In addition, the particular embodiments discussed below are illustrative only and not intended to be limiting.
Brief Description Of The Drawings The invention is pointed out with particularity in the appended claims. The above and further advantages of this invention may be better understood by referring to the following description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a cross-sectional view of a nanoparticle of the invention.
FIG. 2 is a flowchart illustrating general steps involved in a method of making nanoparticles of the invention.
FIGs. 3A-D are schematic views illustrating a method of the invention.
Detailed Description The invention is based on a method for preparing silica-coated nanoparticles using a water-in-oil microemulsion. The method yields uniformly-sized particles composed of a core enveloped by a silica shell. The microemulsion is made by combining a relatively polar liquid such as water, a relatively non-polar liquid such as a liquid alkane, and one or more surfactants to form an isotropic, thermodynamically stable single-phase system. This system is comprised of a plurality of very small spherical water pools (i.e., reverse micelles) that serve as reactors for producing nanoparticle cores. After the cores are produced, they are coated with silica using a silicating agent such as tetraethylorthosilicate (TEOS). In some applications, the silica coating is derivatized with one or more functional groups to yield nanoparticles particularly suited for specific applications. The below described preferred embodiments illustrate various adaptations of the invention. Nonetheless, from the description of these embodiments, other aspects of the invention can be readily fashioned by making slight adjustments or modifications to the components discussed below.
Nanoparticle Characteristics In brief overview, refeiTing to FIG. 1, a preferred nanoparticle 10 of the invention includes a core 12, a shell 14 coating core 12, and one or more functional groups 16 derivatized onto shell 14. Although the diameter of nanoparticle 10 can range from about 1 nm to about 1000 nin or larger, for many applications it is preferably between about 10 nm to about 300 nm (e.g., about 10, 15, 20, 25, 30, 35, 50, 75, 100, 150, 200, 250, or 300 nm). In a dispersion of a plurality of nanoparticles 10, the size distribution preferably has a standard deviation of no more than about 25% (e.g., 1, 2, 3, 5, 10, 15, 20, and 25%) of the average diameter (or largest straight dimension) of the plurality of nanoparticles 10.
The nanoparticle 10 illustrated in FIG. 1 is solid (i.e., substantially without pores).
While this form is preferred for many applications, nanoparticles within the invention can also be porous. Solid forms can be prepared as described below by uniformly coating core 12 with shell 14. Porous forms can be made by degrading a solid nanoparticle with a corrosive agent (e.g., a very basic solution where shell 14 is composed of silica), and optionally re-coating core 12 with silica. In general, solid forms are preferred when it is desired to sequester core 12 from the outside environment; whereas porous forms are preferred when it is desired to increase the surface area of shell 14 in contact with the outside environment (e.g., where nanoparticle 10 is used a catalyst) or sometimes when nanoparticle 10 is used to isolate various substances (e.g., for "trapping" substances within the pores).
Pores in nanoparticle 10 can be of any suitable size less than the diameter of nanoparticle 10. For example, such pores can average about 0.2, 0.5, 1, 2, 3, 5, 10, 20, 50, or 100 nm in size.
Core 12 can be composed of any substance compatible with shell 14. As core 12 imparts functional characteristics on nanoparticle 10, one skilled in the art can select the composition of core 12 to suit the particular application intended for nanoparticle 10 based on known characteristics of compositions. For example, in a preferred embodiment where nanoparticle 10 is desired to be magnetic, core 12 is made up of a magnetic metal such as magnetite (Fe304), maghemite (yFe2O3), or greigite (Fe3S4). In this exainple, the composition of core 12 imparts a magnetic quality on nanoparticle 10 such that nanoparticle 10 can be used for magnetically based applications, e.g., cell separation/purification, diagnostic imaging, recording media, etc. Depending on the particular application, magnetic core 12 can be either superparamagnetic or single-domain (i.e., with a fixed magnetic moment).
Superparamagnetic particles are preferred in applications where particles having a fixed magnetic moment are not desired; whereas single-domain particles are preferred when particles having a fixed magnetic moment are desired, e.g., in magnetic recording media or for biomedical applications that require mechanical transduction (single-domain particles used to impart a torque).
For other applications, core 12 can be made up of non-magnetic metals or metal salts (e.g., gold, silver, cadmium sulfide, etc.). For example, nanoparticles having CDs cores coated with silica can function can be used as quantum dots, i.e., particles having charge carriers surrounded in all directions by potential barriers and which have quantized energy levels that can be used as highly flourescent or luminescent probes, or semiconductors. As another example, for the production of dye or pigment nanoparticles, core 12 can include inorganic salts useful in preparing "pigmentless" pigments, e.g., europium salts, tris(2,2'-bipyridyl) dichlororuthenium, potassiuin permanganate, potassium dichromate, nickel sulfate, cobalt chloride, iron(III) chloride, copper nitrate, etc.
Core 12 can also be composed of a mixture of different substances. For example, where it is desired to make a magnetic, dye-doped nanoparticle, core 12 can be composed of both a magnetic metal and an inorganic salt useful as a pigment. Where core 12 is composed of a material that is very soluble in coinmon solvents (e.g., those typically used in paints and colored-coatings), it is especially desirable that such cores be coated with a substance that resists dissolution or degradation in such solvents.
Core 12 can be of any size less than the size of nanoparticle 10. Thus, core 12 can have a diameter of between less than 1 and 1000 nm. For many applications, core 12 preferably has a diameter ranging from about 1 to about 200 nm. As one example, because animals are able to excrete nanoparticles sized less than about 100 nm, but retain particles greater than 100 nm (primarily in the liver and spleen), cores small enough to be incorporated in nanoparticles less than 100 nm in size are prefelTed in diagnostic or therapeutic applications where is it desired that the nanoparticles not be retained in a subject.
When made using a inicroemulsion nanoparticle-manufacturing technique (see below), core 12 generally has a spheroid shape (conventional reverse micelles are spheroid).
Core 12, however, is not limited to a spheroid shape. For example, rather than being perfectly round, nanoparticle 10 can be oblong or tube-like, a shape preferred in many magnetic applications. Where core 12 is in crystalline form, nanoparticle 10 can have a regular or irregular polyhedral shape such as a cuboid shape.
Shell 14 is a substance that coats core 12. It can be coinposed of any compatible material that can be coated onto core 12 using the methods of the invention.
Shell 14 can, for example, be composed of a polymer (e.g., polystyrene, polyethylene, polyvinyl chloride, an acrylic polymer, etc.), a polysaccharide such as dextran, an inorganic oxide such as alumina or silica, or mixtures of the foregoing. In the presently preferred embodiment, shell 14 is composed partially or entirely of silica. Silica is preferred in various applications as it is relatively inert in many environments, is biocompatible, prevents agglomeration with other nanoparticles in a dispersion, and can be readily derivatized with many different function groups. And while FIG. 1 shows shell 14 configured in a single layer, it can also be multi-layered. For example, shell 14 can include a first layer of silica coating and immediately adjacent to core 12, and a second layer coating the silica layer. The second layer can be composed of any substance that be coated onto the first layer. For example, the second layer can be composed of a biodegradable material (e.g., a sugar or polymer) iinpregnated with a drug. When introduced to an animal, the biodegradable material and drug will gradually be dissolved into the animal. In other applications, shell 14 can be composed of 3, 4, 5 or more separate layers.
In the preferred embodiment shown in FIG. 1, shell 14 is shown completely enveloping core 12 and tlius sequestering core 12 from the outside environment. This form is preferred where it desired to prevent interaction of core 12 with external factors. For example, a silica coating can prevent corrosion of an iron-based core.
Similarly, a coinplete silica coating can enllance the shelf life a nanoparticle-based pigment by preventing degradation or dissolution of the pigment in a solvent or by oxidation. In some variations, nanoparticle 10 does not include a shell 14 or is only partially coated with a shell 14 (e.g., where shell 14 has been partially dissolved or degraded off core 12).
Shell 14 can be of any thickness (i.e., length from outside surface of core 12 to outside surface of shell 14) compatible with the methods of makirig nanoparticle 10.
Using preferred methods of the invention, shell 14 can be made to have a thickness ranging from less than about 1 nm to greater than about 300 nm. Depending on the particular application that nanoparticle 10 is to be used in, the preferred thicknesses of shell 14 will vary. For example, a relatively thick shell is generally preferred where it is desired to reduce agglomeration of nanoparticles (where the cores attract one another) or degradation of the shell (e.g., in a caustic solvent). On the other hand, where it is desired to ainplify the properties of the core (e.g., color of a pigment), a relatively thinner shell is generally preferred.
As shown in FIG. 1, functional groups 16 can be derivatized onto the surface of shell 14. Functional groups 16 can take the form of any chemical or biological group that can be attached to nanoparticle 10 via shell 14. For example, functional groups 16 can be one or more of proteins such as antibodies (monoclonal, polyclonal), enzymes, biotin, and streptavidin; nucleic acid molecules (e.g., RNA, DNA); chemosensors such as fluorescent probes; and biochemical groups such as amines and carboxylates.
Methods of Making Nanoparticles Referring now to FIG. 2, a preferred method of making nanoparticles includes:
a step 50 of providing a microemulsion; a step 52 of providing aqueous solutions of reactants; a step 54 of adding the aqueous solutions to separate aliquots of the microemulsion;
a step 56 of mixing the aliquots to form a reaction mixture that produces nanoparticle cores; and a step 58 of adding a coating agent to the cores to fonn coated nanoparticles.
The microemulsion of step 50 can be made by mixing together at least two immiscible liquids in the presence of at least one surfactant to form a thermodynamically stable, optically isotropic dispersion of nanosize droplets of one or both liquids in the other.
The dispersion is stabilized by the surfactant reducing the surface tension at the interface of the two liquids.
Microemulsions can be either water-in-oil (i.e., reverse micelles or water droplets dispersed in oil), oil-in-water (i.e., micelles or oil droplets dispersed in water), or a bi-continuous system containing coinparable ainounts of two iinmiscible fluids. In some cases, microemulsions can be made by mixing togetller two non-aqueous liquids of differing polarity with negligible mutual solubility. For use in the invention water-in-oil inicroemulsion are presently preferred because they are compatible with very many lcnown chemical reactions for precipitating solids in aqueous solutions.
The immiscible liquids that can be used in step 50 typically include a relatively polar (i.e., hydrophobic) liquid and a relative non-polar (i.e., hydrophillic) liquid. While a large variety of polar/nonpolar liquid mixtures can be used to form a microemulsion useful in the invention, the choice of particular liquids utilized will depend on the type of nanoparticles being made. A skilled artisan can select specific liquids for particular applications by adapting known methods of making microemulsions for use in the present invention. The presently preferred relatively polar liquid is water, although other polar liquids might also be useful. Water is preferred because it is inexpensive, readily available, non-toxic, easy to handle and store, compatible with a large number of different precipitation reactions, and immiscible in a large number of nonpolar solvents. Examples of suitale non-polar liquids include alkanes (e.g., any liquid form of hexane, heptane, octane, nonane, decane, undecane, dodecane, etc.), cycloalkanes (e.g., cyclopentane, cyclohexane, etc.), aromatic hydrocarbons (e.g., benzene, toluene, etc.), and mixtures of the foregoing (e.g., petroleum and petroleum derivatives). In general, any such non-polar liquid can be used as long as it is compatible with the other components used to forin the microemulsion and does not interfere with the involved precipitation reaction.
Step 50 requires at least one surfactant to form a microemulsion. Surfactants are surface active agents that thermodynamically stabilize the very small dispersed micelles or reverse micelles in inicroemulsions. Typically, surfactants possess an amphipathic structure that allows them to form films with very low interfacial tension between the oily and aqueous phases. Thus, any substance that reduces surface tension at the interface of the relatively polar and relatively non-polar liquids and is compatible with other aspects of the invention can be used to form the microemulsion used to make nanoparticles. The choice of a surfactant will depend on the particular liquids utilized and on the type of nanoparticles being made.
Specific surfactants suitable for particular applications can be selected from known methods of making microemulsions or known characteristics of surfactants. For example, non-ionic surfactants are generally preferred when an ionic reactant is used in the microeinulsion process and an ionic detergent would bind to or otherwise interfere with the ionic reactant.
Numerous suitable surfactants are known. A nonexhaustive list includes soaps such as potassium oleate, sodium oleate, etc.; anionic detergents such as Aerosol OT, sodium cholate, sodium caprylate, etc.; cationic detergents such as cetylpyridynium chloride, alkyltrimethylammonium bromides, benzalkonium chloride, cetyldimetllyletliylammonium bromide, etc; zwitterionic detergents such as N-allcyl-N,N-dimethylammonio-1-propanesulfonates and CHAPS; and non-ionic detergents such as polyoxyethylene esters, polyoxyethylene ethers, polyoxyetliylenesorbitan esters, sorbitan esters, and various tritons (e.g., (TX-100, TX-114); etc.
The concentration of surfactant used in step 50 will depend on many factors including the particular surfactant selected, liquids used, and the type of nanoparticles to be made.
Suitable concentrations can be determined empirically, i.e., by trying different concentrations of surfactant until the concentration that performs best in a particular application is found.
Ranges of suitable concentrations can also be determined from known critical micelle concentrations.
In preferred embodiments bis (2-ethylhexyl) sulfosuccinate sodium salt (Aerosol OT, AOT ) is used to create a microeinulsion of water and isooctane;
cetyltrimethylanuiuionium bromide (CTAB) is used to create a microemulsion of n-hexane, n-hexanol, and water; and triton X- 100 (TX- 100) is used to make a microemulsion of cyclohexane, n-hexanol, and water.
Although, in most applications the invention, step 50 employs only one surfactant to stabilize the microemulsion, one or more cosurfactants can also be used. The use of a cosurfactant is sometimes advantageous for stabilizing reverse micelle systems. For example, adding an aqueous surfactant such as soap to a mixture of oil and water yields a milky emulsification. Adding a co-surfactant such as an alcohol of intermediate chain length causes the milky emulsion to clear spontaneously due to formation of very small spheres of dispersed water droplets in oil. Such cosurfactants function by fi,irther reducing the interfacial tension between the phases to facilitate the forination of very small particles of dispersed phase. Suitable co-surfactants for use in the invention include hexanol, butanol, pentanol, octanol, and like intermediate chain length alcohols.
The microemulsion of step 50 is prepared by simply mixing together a relatively polar liquid, a relatively non-polar liquid, and one or more surfactants. For preparing a water-in-oil microemulsion (having aqueous reverse micelles), the volume of the relatively non-polar liquid vastly exceeds that of the relatively polar liquid (e.g., non-polar liquid:polar liquid voluine ratio between about 10000:1 to 100:1). While addition of the surfactant can sometimes cause a microemulsion to form without further agitation, generally the mixture is mechanically (e.g., magnetically) stirred or ultrasonicated to form the microemulsion. Many microemulsions useful in the invention can be prepared at room temperature (i.e., about 20 C) without addition of heat. In other cases, to hasten microemulsion formation by increasing the solubility of the surfactant in the liquids, the mixture of ingredients is sometimes heated (e.g., using a hot plate) to between about 25-80 C.
Referring again to FIG.2, step 52 of providing aqueous solutions of reactants and step 54 of adding the aqueous solutions of step 52 to separate aliquots of a microemulsion can be performed using a water-in-oil microeinulsion prepared as described above.
Steps 52 and 54 can be accomplished by first providing a first water-soluble reactant (reactant A) and a second water-soluble reactant (reactant B), and then adding reactant A to a first aliquot of a water-in-oil microemulsion and reactant B to a second aliquot of a water-in-oil microemulsion. The two aliquots are separately mixed until reactant A reaches equilibrium distribution in each reverse niicelle (reverse micelles continuously form, coalesce, and break apart in the microemulsion, thereby allowing any reactant contained therein to be distributed equally among the reverse micelles) of the first aliquot, and reactant B reaches equilibrium distribution in each reverse micelle of the first aliquot. In step 56, after allowing for the distribution of the dissolved species to equilibrate, the two aliquots are mixed together. Due to collision and coalescence of the reverse micelles, the cations of reactant A and anions of reactant B contact each other and react to form precipitates that serve as nanoparticle cores.
Reactants A and B are generally selected so that they can react to form a precipitate within the reverse micelles of the microemulsions. They are typically soluble in the aqueous reverse micelles and may be solids, liquids, or gases. In a preferred embodiment, Reactant A
is a salt (e.g., with the hypothetical formula A+X") that dissolves into soluble cations (e.g., A+'s) within the reverse micelles of the first aliquot of the microemulsion, and Reactant B is another salt (e.g., with the hypothetical formula BY-) that dissolves into soluble anions (e.g., Y"'s) within the reverse micelles of the second aliquot of the microemulsion.
The cations of Reactant A and anions of Reactant B are selected so that they form a precipitate (A+Y-)when mixed together in an aqueous solution.
While the foregoing illustrates a preferred method of the invention, other methods for making nanoparticle cores using microeinulsions are also within the invention.
Many of these can be perfonned by making slight modifications to the preferred method just.
described. For example, rather than mixing together two different aliquots of a microemulsion, the core-fonning reaction can be carried out using a single aliquot of a microemulsion. In this case, a reactant can be added to the single aliquot and allowed to dissolve and equilibrate among the reverse micelles of the microemulsion.
Subsequently, a precipitating (e.g., reducing or oxidizing) agent in the form of a liquid or gas (e.g., hydrogen, hydrazine, NH4OH) is added to the single aliquot to precipitate the reactant dissolved in the reverse micelles.
Nanoparticle cores can be isolated from a microemulsion by adding a solvent such as acetone or ethanol to the microemulsion and then filtering and/or centrifuging the mixture to isolate the nanoparticles. For filtering, filters have pores sized smaller than the nanoparticles.
For centri-fuging, the mixture can be spun at 10,000 RPM or more in a microcentrifuge for 15 minutes or more to pellet the nanoparticles and the supernatant can be decanted.
Nanoparticles isolated in this manner can be washed one or more times with acetone or an ethanol/water solution to remove any surfactant or other microemulsion component. The isolated and washed nanoparticles can be dried over acetone. Prior to use or functionalization, the nanoparticles can be resuspended in an appropriate liquid.
Using the water-in-oil microemulsion technique, nanoparticle core size is highly controllable. Althougli core size generally relates to reverse micelle size, this is not necessarily a strict relationship as core size does not always correlate with the amount of reactant(s) originally present in each reverse micelle. For example, even small nanoparticle cores (e.g., having diameters of 2 nm to 5 nm) contain from about 300 to 1000 atoms, which is in most cases appreciably larger than the number of reactant molecules present in each micelle prior to reaction. This indicates that nanoparticle core nuclei first form in a small fraction of micelles; these then consume the reactant(s) in other micelles through collision-coalescence processes.
A factor to consider in nanoparticle core preparation therefore is the rate at which nanoparticle cores form. The rate at wliich nanoparticle cores form directly relates to the rate at which the reverse micelles coalesce. Thus, the specific surfactant selected strongly influences the core formation rate, controlling the rate of reverse micelle coalescence. That is, surfactants that result in a relatively rigid interface between the two immiscible liquids of the microemulsion decrease the core formation rate, while surfactants that result in a fluid interface increase the rate. Other properties of the microemulsion, such as ionic strength, pH, and temperature can also be manipulated to control the rate of core formation.
Through empirical adjustment of initial reactant concentrations and microemulsion compositional parameters, nanoparticle cores with homogeneous size distribution (e.g., percentage standard deviation in core size is between about 1 and 5% (for instance, 1, 2, 3, 4, and 5%)) and average diaineters ranging from about 1 nm to about 300 nm or more. Cores of larger size (e.g., about 1 micron) can be prepared by: (i) adding a higher concentration of reagent(s) to the reaction medium (e.g., reverse micelles of the microemulsion), and/or (ii) sonochemically (i.e., by ultrasonication) dispersing isolated cores in a suitable solvent other than microemulsion to make a uniform core suspension, and then adding additional reagent to the dispersion. In the latter method, individual cores often fuse.
In most cases, nanoparticle cores made according to the water-in-oil microemulsion technique described above have a spheroid shape (conventional reverse micelles are spheroid). By altering various parameters in the core formation process, it is possible to produce cores having other shapes. For example, oblong or tube-shaped cores can be made by adding very high concentration of sodium dodecyl sulfate to the microemulsion. As another example, where reactants are selected such that the formed cores have a crystalline structure, nanoparticle cores having a regular or irregular polyhedral shape can be made.
Magnetic nanoparticles can be made using magnetic materials such as magnetite, maghemite, and greigite as part of the core. By varying the overall size and shape of such magnetic cores, they can be made superparamagnetic or stable single-domain (particles that retain a stable magnetic moment after being removed from a magnetic field).
Core size relates to whether a magnetic nanoparticle is superparamagnetic or single-domain.
Thus, relatively equidimensional superparamagnetic particles generally have a core sized less than 50 to 80 nm. At particle sizes above this upper range, the magnetization of the particle is split into domains of differing magnetization vectors in order to minimize internal magnetic energies.
Referring once again to FIG. 2, methods of making nanoparticles within the invention feature a step 58 of adding a coating agent to form coated nanoparticles. The coating agent used in step 58 can be any that causes silica (or another substance) to be deposited onto the surface of the nanoparticle cores. Presently preferred reagents include reactive silicates such as tetraethylorthosilicate (TEOS) or aminopropyltrimethoxysilane (APTS) (both available from Sigma, St. Louis). To coat cores, such reactive silicates are simply added to a solution of nanoparticle cores (e.g., the microemulsion in which the cores were prepared) along with a reducing agent such as aminonium hydroxide or NaOH. The mixture can be stirred for a suitable amount of time to allow the cores to become coated with silica.
Thickness of the silica coating, and the reaction rate for the formation of silica coating are dependent on the amount of reactive silicate added, reaction time, amount of reducing agent added, and reverse micelle size (wliere coating is performed in a water-in-oil microemulsion). Increasing the concentration of the reducing agent (e.g, [NH4OH]) to reactive silicate concentration (e.g., [TEOS]) generally results in a thiclcer coating forming after a given reaction time. Increasing the concentration of polar liquid (e.g., water) to reactive silicate concentration generally results in a thinner coating forming after a given reaction time. The precise reaction conditions for controlling the thickness of the coating will vary according to the particular agent used, the core material, etc. These, however, can be deteimined empirically by simple experiments varying the concentrations of reagents and reaction times and conditions.
Methods within the invention can also include a step of functionalizing (i.e., derivatizing with one or more functional chemical groups) coated nanoparticles made as described above. Numerous known methods for attaching functional groups to silica can be adapted for use in the present invention. See, e.g., Ralph K. Iler, The Chemistry of Silica:
Solubility, Polymerization, Colloid and Surface Properties, and BiochemistrY, Wiley-Interscience, NY, 1979; VanDerVoort, P. and Vansant, E. F., Journal of Liquid Chromatography and Related Technologies, 19:2723 -2752, 1996; and Immobilized Enzymes, Antigens, Antibodies, and Peptides: Preparation and Characterization, Howard H. Weetall (ed.), M. Dekker, NY, 1975. A typical process for adding functional groups to silica-coated nanoparticles involves treating the nanoparticles with a silanizing agent that reacts with and couples a chemical group to the silica surface of the nanoparticles. The chemical group can itself be the functional group, or it can serve as a substrate to which functional groups can be coupled.
For example, in an exemplary method, silica-coated nanoparticles are prepared as described above and the particle surfaces are silanized using trimethylsilylpropyl-diethylenetriamine (DETA), a silanization agent that attaches primary amine groups to silica surfaces. Antibodies or other proteins can then be covalently coupled to the silanized surface using the cyanogen bromide (CNBR) method. As one example, CNBR-mediated coupling can be achieved by suspending silica-coated nanoparticles previously silanized with DETA in a 2 M sodium carbonate buffer and ultrasonicating the mixture to create a particle suspension.
A solution of CNBR (e.g., 2 g CNBR/1 ml acetonitirile) is then added to the particle suspension to activate the nanoparticles. After washing the nanoparticles with a neutral buffer (e.g., PBS, pH 8), an antibody solution is added to the activated nanoparticle suspension causing the antibodies to become bound to the nanoparticles. A
glycine solution can also be added to the antibody-coated nanoparticles to block any remaining unreacted sites.
Methods of Using Nanoparticles Nanoparticles of the invention to isolate cells (e.g., eukaryotic or prokaryotic cells).
One such method is illustrated in FIG. 3. Referring to FIG. 3A, antibody-derivatized magnetic nanoparticles 10 are shown mixed with target cells 20 and non-target cells 21 in container 30. Target cells 20 express a target antigen 22 on their surface, while non-target cells 21 do not. In the nanoparticles shown, core 12 includes a ferrous material such as magnetite or maghemite, and functional groups 16 include an antibody that can specifically bind target antigen 22. Referring now to FIG. 3B, nanoparticle 10 is shown physically binding target ce1120 via the interaction of functional groups 16 and target antigen 22. Such binding spontaneously results when nanoparticle 10 and target cel120 are mixed together in container 30 under conditions which allow antibody-antigen binding (e.g., about room temperature, neutral to slightly basic pH in a low salt buffer). Non-target cells 21 do not specifically bind nanoparticles 10 because they do not express target antigen 22. As shown in FIG. 3C, application of a magnetic field to the nanoparticle-cell mixture by insertion of magnet 32 into container 30 causes nanoparticles 10 and bound target cells 21 to associate with magnet 32. Referring to FIG. 3D, by removing magnet 32 from container 30, target cells 20 can be isolated. Cells 20 can be separated from nanoparticles 10 using an excess of soluble antigen.
Many other applications are specifically envisioned including, for example, cell labeling (see Exaiuple 8 below), targeted drug or gene delivery, biosensors, magnetic recording media, magnetic resonance imaging, and use in micro- or nano-sized machines.
For example, cytotoxic drugs or viral vectors carrying therapeutic genes can be attached to the functional groups on the surface of nanoparticles. These nanoparticles can then be dispersed in a pharmaceutically acceptable carrier (e.g., USP grade saline) and administered to a patient (e.g., by intravenous injection). Magnetic fields can then be used to concentrate the virus or drug at the delivery site to enhance site-specific uptalce (e.g., by placing a magnet at the site).
Drugs coated onto nanoparticles can be further contained witliin a time-release coating (e.g., a biodegradable sugar) so that the drug can accuinulate at the site before becoming active.
In other envisioned examples, fluorescence-based biosensors can be attached to the particles. The resulting particles can be manipulated by magnetic means into specific target sites (specific locations in isolated cells), and used to monitor biochemical processes in situ.
The nanoparticles of the invention are also thought to be useful for enhancing Magnetic Resonance Images (MRI). For example, as described above, antibody or ligand-coated nanospheres can be caused to accumulate at sites in the body where the target antigen or receptor is concentrated or located. In comparison to non-targeted MRI
contrast agents, the increased concentration of particles at a targeted site will enhance the contrast in an MRI.
Nanoparticles manufactured in a stable, single domain size range that allows a remnant magnetization to be preserved are envisioned to be useful in binary magnetic recording applications where they can be substituted for the simple iron particles used in conventional magnetic storage devices. For example, arrays of ferrite-doped silica particles could be tailored for minimum magnetostatic interactions to permit individual nanoparticles to be magnetized either parallel or antiparallel to their easy axis of magnetization for binary data storage applications. And because stable single domain particles are able to transduce applied magnetic fields as mechanic motion (i.e. a torque can be exerted on the particle when a magnetic field is applied at an angle to the easy axis of magnetization), arrays of these nanoparticles of the invention could find use as mechanical micro- or nanomachines. One particular example would be micromechanical gate activation upon application of an external magnetic field.
Examples Exainple 1-Preparation of Silica-Coated Magnetite Nanoparticles by Microemulsion:
(A) A 0.27 M bis (2-ethylhexyl) sulfosuccinate sodium salt (Aerosol OT or AOT
) solution was prepared by dissolving 12 g AOT in 10 ml isooctane. An aliquot of ultra-pure water was purged for one hour wit11 Nz gas. A stock solution of 1 M Fe(II) was prepared by dissolving 0.278 g FeSO4 7H20 in 1 ml of the nitrogen purged water. Similarly, a stock solution of 1.5 M Fe(III) was prepared by dissolving 0.4055 g FeC13'6 H20 (0.4055 gm) in 1 ml of the nitrogen purged water. In a glass container, 25 1 of the 1 M Fe(II) solution and 25 l of the 1.5M Fe(III) solution were added to a 5 ml aliquot of the AOT
solution under a nitrogen atmosphere, and the resulting Fe/AOT mixture was magnetically stirred for 1 hr to form a Fe/AOT solution. In another container, 100 l NH4OH (28-30 wt%) was added to another 5 ml aliquot of the AOT solution, and the resulting NH¾OH/AOT mixture was magnetically stirred for 1 hr to form a NH4OH/AOT solution. In absence of magnetic field, the NH4OH/AOT solution was added dropwise to the Fe/AOT solution with vigorous mechanical stirring for 1 hr. Initially a light yellow solution formed. This solution turned brown (without any precipitate formation) as magnetite nanoparticles formed.
50 l of tetraethylorthosilicate (TEOS) was then added to the resulting brown solution and mechanical stirring was continued for an additional 24 hrs. Silica-coated unifomz-sized nanoparticles in powder form were obtained by coagulating the colloidal microemulsion with acetone, and then filtering and washing the particles with acetone and ethanol several times with each solvent. In some cases, 50% (v/v) solution of ethanol/water was also used for washing.
(B) 1.78 g of AOT was dissolved in 20.0 ml of isooctane. The resulting solution was mixed using a sonicator and flushed with nitrogen. 100 L each of Nz flushed 0.10 M
FeSO4 and 0.15 M FeC13 (both prepared in water) were then added and mixed into the solution to form a microemulsion. 100 L of N2-flushed solution of 2.0 M NaOH
was then added, and the resulting microemulsion was sonicated for 1 hour while being continuously flushed with N2. 10 L of TEOS was then added to the sonicated microemulsion, and the mixture was allowed to react overnight. The isooctane contained in the microemulsion was then evaporated and the remaining gel was dissolved in ethanol. This solution was centrifuged to pellet the nanoparticles and the supernatant was discarded.
After washing 3 or 4 more times with ethanol, the resulting nanoparticles were subjected to TEM
which showed that nanoparticles having a diameter of approximately 3-5 nm were produced. A
silica shell was observed as a translucent halo, about 2-3 nin tllick surrounding the denser core.
(C) A microemulsion I (ME I) was prepared by first dissolving 8.89 g AOT in 40.0 ml isooctane to form a first solution. 1.2 ml H20 and 6.0 ml FeSO4 was then added and the mixture was sonicated to form ME I. In another glassware, a microemulsion II (ME II) was similarly prepared by first dissolving 8.89 g AOT and dissolve in 40.0 ml isooctane to form a second solution. 3.2 ml H20 and 4.0 ml NH4OH was added to the second solution, which was then mixed for about 30 minutes to form ME II. 10 L TEOS was added to ME
II, and the mixture was allowed to react for about 2 hours. Using a glass syringe, ME II was slowly added to ME I, and the reaction mixture thus formed was sonicated for 24 hours. As described in (B) above, the isooctane was then evaporated, the remaining gel was dissolved in ethanol and centrifuged to recover the formed nanoparticles which were washed 3 or 4 times with additional ethanol. TEM showed that nanoparticles having a diameter of approximately 25 nm were produced. A silica shell was observed as a translucent halo about 5 nm thick surrounding the denser core.
Example 2- Preparation of Dye-doped Silica-Coated Nanoparticles (A) Preparation of Eu/Bpy (Eu3+/2,2'-dipyridyl)-doped silica nanoparticles in cetyltrimethylammonium bromide (CTAB)/n-hexane/n-hexanol (cosurfactant)/water water-in-oil microemulsions. 90 ml of a water-in-oil microemulsion stock solution was prepared by mixing together 2.916 g CTAB, 75 ml n-hexane, 15 ml n-hexanol and 880 l water using a magnetic stirrer. 10 ml of the stock solution was equally divided into two 5 ml aliquots. 50 l T'EOS and 5 10.1 M Eu/Bpy (aqueous solution) was added to one of the 5 ml aliquots and the mixture was stirred for 1 hr to form a TEOS/Eu/Bpy solution. 137 l NH¾OH
was added to the other 5 ml aliquot and the mixture was stirred for 1 hr to form an NH4OH solution.
The NH4OH solution was then added dropwise to the TEOS/Eu/Bpy solution and the resulting mixed solution was stirred overnight. The water to surfactant molar ratio of the mixed solution was 15 (water:surfactant). Eu/Bpy-doped silica nanoparticles were isolated in powder form by adding 25 ml of acetone to the microemulsion of the mixed solution, centrifuging the resultant mixture for 15 minutes at 10,00RPM in a microcentrifuge to pellet the nanoparticles, the supernatant was removed and the remaining nanoparticles were washed several times with acetone or an etlianol/water solution to further remove surfactant and other microemulsion components. The washed nanoparticles were then dried over acetone.
(B) Ru/Bpy [RuII(Bpy)3]-doped silica nanoparticles in triton X-100 (TX-100)/
cyclohexane/n-hexanol(cosurfactant)/water water-in-oil microemulsions. 10 ml of a water-in-oil microemulsion was prepared by mixing 7.5 ml cyclohexane, 1.8 ml n-hexanol, 1.77 ml TX-100, 340 l water and 140 10.1 M RuII(Bpy)3 (aqueous solution) for 1 hr with a magnetic stirrer. The resulting solution was then divided into two 5 ml aliquots. 100 1 TEOS was added to one aliquot and the mixture was stirred for 30 minutes to form a TEOS
solution. 60 l of NH4OH was added to the other 5 ml aliquot and the mixture was stirred for 30 minutes to form a NH¾OH solution. The NH4OH solution was then added to the TEOS
solution dropwise for a period of 10 minutes and the resulting mixed solution was stiiTed overnight. Ru/Bpy doped silica nanoparticles were isolated as described above in (A).
Exainple 3- Preparation of Metal-Doped Silica-Coated Nanoparticles ml of a TX-100/cyclohexane/n-hexanol(cosurfactant)/waterwater-in-oil microemulsion stock solution was prepared as described in Example 2(A). The stock solution was equally divided into two 5 ml aliquots. 30 l of a 1M aqueous solution of silver nitrate (AgNO3) was added to one of the 5 ml aliquots and the mixture was stirred for about 30 minutes to form a AgNO3 solution. 11 l of a 2M aqueous solution of sodium borohydride (NaBH4) was added to the other 5 ml aliquot and the mixture was stirred for about 30 minutes to form an NaBH4 solution. The NaBH¾ solution was then added dropwise to the AgNO3 solution for the period of 15 minutes to form a reaction mixture.
After 5 minutes, 10 l of TEOS was added and the resulting mixture stirred for another 15 minutes.
l of a NH4OH solution was then added and stirring was continued overnight. The Ag-doped silica nanoparticles were isolated similar to the procedure described in Example 2(A), i.e., by adding 25 ml of acetone to the microemulsion, filtering, washing several times with an ethanol/water solution to remove surfactant, and finally drying over acetone.
Using a variation of this method cadmiuin sulfide (CDs)-doped silica nanoparticles were also prepared. In this case, cadmium nitrate and ammonium sulfide were used in place of silver nitrate and sodium borohydride, respectively.
Example 4- Preparation of Pi ments A new class of piginents was prepared using regular inorganic salts including potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, and copper nitrate. While these salts are highly water soluble, they become completely insoluble when coated with silica, and thus behaved as pigments.
All were colored and photostable.
These pigments was prepared as described for the Ru/Bpy doped silica nanoparticles described above in Example 2(B), except that a 0.1M salt solution (e.g., potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, and copper nitrate) was used in place of the 0.1 M Ru'I(Bpy)3 solution, and an additional 100 l TEOS and 60 l NH4OH were added to the mixed solution 12 hrs after the 10 ul addition of NH4OH. Pigment particles were separated from the mixture after 24 hrs.
Example 5- Characterization of Nanoparticles Transmission electron microscopy (TEM) and other analyses were used to characterize of the size of various nanoparticles made according to the invention. As one exainple, RuII(Bpy)3 nanoparticles were prepared as described in Example 2(B) and subjected to TEM. By analyzing photographs of the TEM images, it was deterinined that the RuII(Bpy)3 nanoparticles had a core size of about 20 nm (standard deviation= +/-2 nm) and an overall particle size of about 100 nm (standard deviation= +/-10 nm). Smaller and larger silica-coated nanoparticles were also prepared by varying the preparation conditions specified above. For example, those with core sizes even as small as 2 nm (e.g., sized to prepare quantum dots) with constant or varied thickness (as large as 300 nm) of the outer silica coating have been prepared. Nanoparticles useful as pigments (see Example 5) were also subjected to TEM which showed that such particles were sized between 0.2 and 0.3 m. In other analyses, compared to commercially available conventional dyes, dye-doped nanoparticles made according to the invention proved extremely resistant to bleaching even after strong excitation from a laser source. Similarly, no fluorescence quenching was observed in fluorescent dye-doped nanoparticles.
Example 6- Preparation of a Nanoparticle-based Chemosensor Dye-doped, silica-coated nanoparticles were prepared using a water-in-oil microemulsion technique. The water-in-oil microemulsion was prepared first by mixing Triton X- 100 (TX- 100), cyclohexane, n-hexanol (4.2:1:1 VN) and an adequate amount of water. An aqueous dye solution (RuII(Bpy)3; (see example 3B above) was then added to the microemulsion in such a way that the water to surfactant molar ratio was kept constant at 10.
The final dye concentration in the mixture was 0.1 M. TEOS was then added to the mixture.
A polymerization reaction was initiated by adding NH4OH (volume ratio of TEOS
to NH¾OH
was 1.7), and the reaction was allowed to continue for 12 hours. After the reaction was complete, the dye-doped silica nanoparticles were isolated by adding acetone to the reaction, followed by centrifuging and washing with ethanol and water for several times.
The nanoparticles were then stored in aqueous solution for later usage.
The dye-doped silica nanoparticles produced were uniform in size, as characterized by transmission electron microscopy (TEM) and atomic force microscopy (AFM). A
TEM
image of the dye-doped silica particles showed that the particles were 60 10 nm in size and uniform. At a higher resolution, the luininescent complex of RuBpy dye aggregates were also visible as darker dots embedded inside the silica sphere due to the presence of heavy metal atom in these dye molecules. These individual dye aggregates were as small as 1 nm.
To investigate whether the RuBpy molecules doped inside the silica network could function as an oxygen sensor, the fluorescence emission spectra of free RuBpy molecules was coinpared to that of the RuBpy-doped nanoparticles at various air pressures.
With the free RuBpy dye molecules, the intensity of the emission was greatly decreased as the air pressure was increased from 1 to 14 psi. In contrast, under the same conditions, no significant change in the emission spectra for the dye-doped silica-coated nanoparticles was observed, indicating that the silica network was essentially impermeable to oxygen molecules. In other experiments, the dye-doped silica-coated nanoparticles also showed excellent photostability even upon intensive laser illumination.
Example 7- Functionalized Silica-Coated Nanoparticles The dye-doped, silica-coated nanoparticles of Example 6 were derivatized with antibodies by first silanizing the particle surfaces with DETA, a silanization agent that attaches the primary amine group to silica surfaces. Using fluorescamine, a non-fluorescent molecule that becomes highly fluorescent upon reacting with the primary aliphatic amine group (Cordek, J. Wang, X and Tan W., Anal Chein, 71, 1529-1533, 1999; Chung, L. A. Anal Biochem. 1997,248,195), the presence of amine group on the surface of the nanoparticles was confirmed.
After surface silanization with DETA, an antibody (mouse anti-human CD 10) was immobilized onto the silanized silica surface using the cyanogen bromide (CNBR) method.
Dye-doped particles (26 g) were prepared as described in Example 6, dried, and then suspended in 9.0 m12 M sodium carbonate solution (activation buffer) using ultrasonication.
A solution of CNBR in acetonitrile (1.0 gm of CNBR dissolved in 0.5 ml acetonitrile) was then added dropwise to the particle suspension (10 mg/ml) under stirring for 5 minutes at room teinperature. The resulting CNBR-activated particles were washed twice with ice-cold water and twice with PBS buffer (pH 8.0).
40 l of the antibody diluted in PBS buffer (pH 8.0) was then added to the surface modified particles, and stirring was continued for 24 hours at 4 C. The resulting antibody-derivatized nanoparticles were then treated with 10 ml of 0.03 M glycine solution for 30 minutes to block any remaining reactive sites. The final product was washed, re-suspended in PBS (pH 8.0) buffer and stored at 4 C for future usage. No change in the optical and spectroscopic properties of the nanoparticles was observed.
Example 8-Cell Labeling Mononuclear lymphoid cells (about 2 million cells/ml) were obtained as a suspension in the cell culture medium. The cell suspension was incubated for 2 hours with the anti-CD 10 immobilized nanoparticles described in Exainple 7. After incubation, the cell suspension was imaged with both optical microscopy and fluorescence microscopy. The microscopic analysis revealed that most of the cells were labeled (indicated by the bright emission of the dye-doped particles). The optical images correlated well with the fluorescence images. In control experiments using non-antibody derivatized dye-doped nanoparticles, no labeling of cells was observed. In the labeled cells, the signal-to-noise ratio (i.e., the ratio between the intensities of the bright and the darlc areas in the fluorescence image) was over 500.
Other Embodiments While the above specification contains many specifics, these should not be construed as limitations on the scope of the invention, but rather as exainples of preferred embodiments tliereof. Many other variations are possible. Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their legal equivalents.
Statement As To Federally Sponsored Research This invention was made with U.S. government support under grant number N00014-98-1-0621 awarded by the Office of Naval Research and grant number NSF
BIO-9871880 awarded by the National Science Foundation. The U.S. government may have certain rigllts in the invention.
Field Of The Invention The invention relates generally to the field of nanoparticles and methods of making nanoparticles. More particularly, the invention relates to silica-coated nanoparticles prepared by using microeinulsions.
Background Of The Invention Nanoparticles are veiy small particles typically ranging in size from as small as one nanometer to as large as several hundred nanometers in diameter. Their small size allows nanoparticles to be exploited to produce a variety of products such as dyes and pigments;
aesthetic or functional coatings; tools for biological discovery, medical imaging, and therapeutics; magnetic recording media; quantum dots; and even uniforin and nanosize semiconductors.
Nanoparticles can be simple aggregations of molecules or they can be structured into two or more layers of different substances. For exainple, simple nanoparticles consisting of magnetite or maghemite can be used in magnetic applications (e.g., MRI
contrast agents, cell separation tools, or data storage). See, e.g., Scientific and Clinical Applications of Ma ng etic Microspheres, U.Hafeli, W. Schutt, J. Teller, and M.Zborowski (eds.) Plenum Press, New York, 1997; Sjogren et al., Magn.Reson. Med. 31: 268, 1994; and Tiefenauer et al., Bioconjugate Chem. 4:347, 1993. More complex nanoparticles can consist of a core made of one substance and a shell made of another.
Many different type of small particles (nanoparticles or micron-sized particles) are commercially available from several different manufacturers including: Bangs Laboratories (Fishers, Indiana); Promega (Madison, WI); Dynal Inc.(Lake Success, New York);
Advanced Magnetics Inc.(Surrey, U.K.); CPG Inc.(Lincoln Park, New Jersey); Cortex Biochem (San Leandro, California); European Institute of Science (Lund, Sweden);
Ferrofluidics Corp.
(Nashua, New Hampshire); FeRx Inc.; (San Diego, California); Immunicon Corp.;
(Huntingdon Valley, Pennsylvania); Magnetically Delivered Therapeutics Inc.
(San Diego, CA); Miltenyi Biotec GmbH (USA); Microcaps GmbH (Rostock, Germany);
PolyMicrospheres Inc. (Indianapolis, IN); Scigen Ltd.(Kent, U.K.); Seradyn Inc.;
(Indianapolis, Indiana); and Spherotech Inc. (Libertyville, Illinois). Most of these particles are made using conventional techniques, such as grinding and milling, emulsion polymerization, block copolymerization, and microemulsion.
Methods of making silica nanoparticles have also been reported. The processes involve crystallite core aggregation (Philipse et al., Langmuir, 10:92, 1994);
fortification of superparamagnetic polymer nanoparticles with intercalated silica (Gruttner, C
and J Teller, Journal of Magnetism and Magnetic Materials, 194:8, 1999); and microwave-mediated self-assembly (Correa-Duarte et al., Langmuir, 14:6430, 1998). Unfortunately, these techniques have not proven to be particularly efficient for consistently fabricating nanoparticles with a particular size, shape and size distribution.
Summary Of The Invention The invention relates to a new method for preparing nanoparticles having a core enveloped by a silica (SiOZ) shell.. Such silica-coated nanoparticles can be used, for example, as dye-doped particles, "pigmentless" pigment particles, metal particles, semiconductor particles, magnetic particles, and drug molecule particles The method employs a microemulsion, i.e., isotropic and thermodynamically stable single-phase system, to produce nanoparticles cores of a predetermined, very uniform size and shape. Cores produced using the microemuslion are then coated with silica using a silicating agent. The nanoparticles thus formed can be customized for a particular application by derivatizing various chemical groups onto the silica coating.
Accordingly, the invention features nanoparticles having a core and a silica shell enveloping the core. The nanoparticles can have a mean size of less than 1 micron (e.g., between 1 nm and 300 nm, or between 2 nm and 10 nm). In some variations, the nanoparticle cores can be magnetic and can include a metal selected from the group consisting of magnetite, maghemite, and greigite. In other variations, the core includes a pigment which can be an inorganic salt such as potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, or copper nitrate. Similarly, the core can include a dye such as Ru/Bpy, Eu/Bpy, or the like; or a metal such as Ag and Cd.
The invention also features nanoparticles with a silica shell that is derivatized with a functional group such as a protein (e.g., an antibody); a nucleic acid (e.g., an oligonucleotide);
biotin; or streptavidin.
Also within the invention is a method of making coated nanoparticles. This method includes the steps of: providing a microemulsion; providing a first aqueous solution of a first reactant and a second aqueous solution of a second reactant (the first reactant and second reactant being selected such that a solid precipitate forms upon mixing the first and second reactants together in an aqueous environment); adding the first aqueous solution to a first aliquot of the microemulsion and the second aqueous solution to a second aliquot of the microemulsion; mixing together the first and second aliquots to form a reaction mixture that reacts to form nanoparticle cores; and adding a coating agent to the cores to form coated nanoparticles.
The microemulsion can be a water-in-oil microeinulsion that can be made by mixing togetller water; a relatively polar liquid such as isooctane, n-hexane, or cyclohexane; a surfactant such as AOT, TX-100, and CTAB; and, in some cases, a cosurfactant such as n-hexanol. The coating agent can be a reactive silicate such as TEOS and APTS.
In some variations, the method includes a step of derivatizing the silica shell with a functional group such as a protein (e.g., an antibody); a nucleic acid (e.g., an oligonucleotide); biotin; or streptavidin. Thus, the method of the invention can be used to malce protein-derivatized, silica-coated nanoparticles having cores including a metal such as magnetite, maglleinite, or greigite.
In another aspect, the invention features a method of identifying cells expressing a preselected molecule. This method includes the steps of: providing a plurality of silica-coated nanoparticles coated with a functional group that binds to a preselected molecule;
providing a plurality of cells at least some of which express the preselected molecule; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture;
placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles. In one variation of this method, the functional group is an antibody that specifically binds to the preselected _ SECTIO!q 8 Cf~P~4~'CT*._-.
I~
S~_ r~`..-6~9z,~ ATg ~ . ~;.
CORi:, LEg V~- '. :: .. . ,+.i CA'1=
molecule. In another variation, the silica-coated nanoparticles are fluorescent.
As used herein, the word "nanoparticle" means a particle having a diameter of between about 1 and 1000 nm. Similarly, by the term "nanoparticles" is meant a plurality of particles having an average diameter of between about 1 and 1000 nm.
For the purposes herein, a microemulsion is defined as a thermodynamically stable, optically isotropic dispersion of two inuniscible liquids consisting of nanosize domains of one or both liquids in the other, stabilized by an interfacial film of surface-active molecules.
By reference to the "size" of a nanoparticle is meant the length of the largest straight dimension of the nanoparticle. For example, the size of a perfectly spherical nanoparticle is its diameter.
By the phrase "specifically binds" means that one molecule recognizes and adheres to a particular second molecule in a sample, but does not substantially recognize or adhere to other molecules in the sample. Generally, an antibody that "specifically binds" a preselected antigen is one that binds the antigen with a binding affinity greater than about 105 to 106 liters/mole.
As used herein, the phrase "functional group" means a chemical group that imparts a particular function to an article (e.g., nanoparticle) bearing the chemical group. For example, functional groups can include substances such as antibodies, oligonucleotides, biotin, or streptavidin that are known to bind particular molecules; or small chemical groups such as amines, carboxylates, and the like.
Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In the case of conflict, the present specification, including definitions will control. In addition, the particular embodiments discussed below are illustrative only and not intended to be limiting.
Brief Description Of The Drawings The invention is pointed out with particularity in the appended claims. The above and further advantages of this invention may be better understood by referring to the following description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a cross-sectional view of a nanoparticle of the invention.
FIG. 2 is a flowchart illustrating general steps involved in a method of making nanoparticles of the invention.
FIGs. 3A-D are schematic views illustrating a method of the invention.
Detailed Description The invention is based on a method for preparing silica-coated nanoparticles using a water-in-oil microemulsion. The method yields uniformly-sized particles composed of a core enveloped by a silica shell. The microemulsion is made by combining a relatively polar liquid such as water, a relatively non-polar liquid such as a liquid alkane, and one or more surfactants to form an isotropic, thermodynamically stable single-phase system. This system is comprised of a plurality of very small spherical water pools (i.e., reverse micelles) that serve as reactors for producing nanoparticle cores. After the cores are produced, they are coated with silica using a silicating agent such as tetraethylorthosilicate (TEOS). In some applications, the silica coating is derivatized with one or more functional groups to yield nanoparticles particularly suited for specific applications. The below described preferred embodiments illustrate various adaptations of the invention. Nonetheless, from the description of these embodiments, other aspects of the invention can be readily fashioned by making slight adjustments or modifications to the components discussed below.
Nanoparticle Characteristics In brief overview, refeiTing to FIG. 1, a preferred nanoparticle 10 of the invention includes a core 12, a shell 14 coating core 12, and one or more functional groups 16 derivatized onto shell 14. Although the diameter of nanoparticle 10 can range from about 1 nm to about 1000 nin or larger, for many applications it is preferably between about 10 nm to about 300 nm (e.g., about 10, 15, 20, 25, 30, 35, 50, 75, 100, 150, 200, 250, or 300 nm). In a dispersion of a plurality of nanoparticles 10, the size distribution preferably has a standard deviation of no more than about 25% (e.g., 1, 2, 3, 5, 10, 15, 20, and 25%) of the average diameter (or largest straight dimension) of the plurality of nanoparticles 10.
The nanoparticle 10 illustrated in FIG. 1 is solid (i.e., substantially without pores).
While this form is preferred for many applications, nanoparticles within the invention can also be porous. Solid forms can be prepared as described below by uniformly coating core 12 with shell 14. Porous forms can be made by degrading a solid nanoparticle with a corrosive agent (e.g., a very basic solution where shell 14 is composed of silica), and optionally re-coating core 12 with silica. In general, solid forms are preferred when it is desired to sequester core 12 from the outside environment; whereas porous forms are preferred when it is desired to increase the surface area of shell 14 in contact with the outside environment (e.g., where nanoparticle 10 is used a catalyst) or sometimes when nanoparticle 10 is used to isolate various substances (e.g., for "trapping" substances within the pores).
Pores in nanoparticle 10 can be of any suitable size less than the diameter of nanoparticle 10. For example, such pores can average about 0.2, 0.5, 1, 2, 3, 5, 10, 20, 50, or 100 nm in size.
Core 12 can be composed of any substance compatible with shell 14. As core 12 imparts functional characteristics on nanoparticle 10, one skilled in the art can select the composition of core 12 to suit the particular application intended for nanoparticle 10 based on known characteristics of compositions. For example, in a preferred embodiment where nanoparticle 10 is desired to be magnetic, core 12 is made up of a magnetic metal such as magnetite (Fe304), maghemite (yFe2O3), or greigite (Fe3S4). In this exainple, the composition of core 12 imparts a magnetic quality on nanoparticle 10 such that nanoparticle 10 can be used for magnetically based applications, e.g., cell separation/purification, diagnostic imaging, recording media, etc. Depending on the particular application, magnetic core 12 can be either superparamagnetic or single-domain (i.e., with a fixed magnetic moment).
Superparamagnetic particles are preferred in applications where particles having a fixed magnetic moment are not desired; whereas single-domain particles are preferred when particles having a fixed magnetic moment are desired, e.g., in magnetic recording media or for biomedical applications that require mechanical transduction (single-domain particles used to impart a torque).
For other applications, core 12 can be made up of non-magnetic metals or metal salts (e.g., gold, silver, cadmium sulfide, etc.). For example, nanoparticles having CDs cores coated with silica can function can be used as quantum dots, i.e., particles having charge carriers surrounded in all directions by potential barriers and which have quantized energy levels that can be used as highly flourescent or luminescent probes, or semiconductors. As another example, for the production of dye or pigment nanoparticles, core 12 can include inorganic salts useful in preparing "pigmentless" pigments, e.g., europium salts, tris(2,2'-bipyridyl) dichlororuthenium, potassiuin permanganate, potassium dichromate, nickel sulfate, cobalt chloride, iron(III) chloride, copper nitrate, etc.
Core 12 can also be composed of a mixture of different substances. For example, where it is desired to make a magnetic, dye-doped nanoparticle, core 12 can be composed of both a magnetic metal and an inorganic salt useful as a pigment. Where core 12 is composed of a material that is very soluble in coinmon solvents (e.g., those typically used in paints and colored-coatings), it is especially desirable that such cores be coated with a substance that resists dissolution or degradation in such solvents.
Core 12 can be of any size less than the size of nanoparticle 10. Thus, core 12 can have a diameter of between less than 1 and 1000 nm. For many applications, core 12 preferably has a diameter ranging from about 1 to about 200 nm. As one example, because animals are able to excrete nanoparticles sized less than about 100 nm, but retain particles greater than 100 nm (primarily in the liver and spleen), cores small enough to be incorporated in nanoparticles less than 100 nm in size are prefelTed in diagnostic or therapeutic applications where is it desired that the nanoparticles not be retained in a subject.
When made using a inicroemulsion nanoparticle-manufacturing technique (see below), core 12 generally has a spheroid shape (conventional reverse micelles are spheroid).
Core 12, however, is not limited to a spheroid shape. For example, rather than being perfectly round, nanoparticle 10 can be oblong or tube-like, a shape preferred in many magnetic applications. Where core 12 is in crystalline form, nanoparticle 10 can have a regular or irregular polyhedral shape such as a cuboid shape.
Shell 14 is a substance that coats core 12. It can be coinposed of any compatible material that can be coated onto core 12 using the methods of the invention.
Shell 14 can, for example, be composed of a polymer (e.g., polystyrene, polyethylene, polyvinyl chloride, an acrylic polymer, etc.), a polysaccharide such as dextran, an inorganic oxide such as alumina or silica, or mixtures of the foregoing. In the presently preferred embodiment, shell 14 is composed partially or entirely of silica. Silica is preferred in various applications as it is relatively inert in many environments, is biocompatible, prevents agglomeration with other nanoparticles in a dispersion, and can be readily derivatized with many different function groups. And while FIG. 1 shows shell 14 configured in a single layer, it can also be multi-layered. For example, shell 14 can include a first layer of silica coating and immediately adjacent to core 12, and a second layer coating the silica layer. The second layer can be composed of any substance that be coated onto the first layer. For example, the second layer can be composed of a biodegradable material (e.g., a sugar or polymer) iinpregnated with a drug. When introduced to an animal, the biodegradable material and drug will gradually be dissolved into the animal. In other applications, shell 14 can be composed of 3, 4, 5 or more separate layers.
In the preferred embodiment shown in FIG. 1, shell 14 is shown completely enveloping core 12 and tlius sequestering core 12 from the outside environment. This form is preferred where it desired to prevent interaction of core 12 with external factors. For example, a silica coating can prevent corrosion of an iron-based core.
Similarly, a coinplete silica coating can enllance the shelf life a nanoparticle-based pigment by preventing degradation or dissolution of the pigment in a solvent or by oxidation. In some variations, nanoparticle 10 does not include a shell 14 or is only partially coated with a shell 14 (e.g., where shell 14 has been partially dissolved or degraded off core 12).
Shell 14 can be of any thickness (i.e., length from outside surface of core 12 to outside surface of shell 14) compatible with the methods of makirig nanoparticle 10.
Using preferred methods of the invention, shell 14 can be made to have a thickness ranging from less than about 1 nm to greater than about 300 nm. Depending on the particular application that nanoparticle 10 is to be used in, the preferred thicknesses of shell 14 will vary. For example, a relatively thick shell is generally preferred where it is desired to reduce agglomeration of nanoparticles (where the cores attract one another) or degradation of the shell (e.g., in a caustic solvent). On the other hand, where it is desired to ainplify the properties of the core (e.g., color of a pigment), a relatively thinner shell is generally preferred.
As shown in FIG. 1, functional groups 16 can be derivatized onto the surface of shell 14. Functional groups 16 can take the form of any chemical or biological group that can be attached to nanoparticle 10 via shell 14. For example, functional groups 16 can be one or more of proteins such as antibodies (monoclonal, polyclonal), enzymes, biotin, and streptavidin; nucleic acid molecules (e.g., RNA, DNA); chemosensors such as fluorescent probes; and biochemical groups such as amines and carboxylates.
Methods of Making Nanoparticles Referring now to FIG. 2, a preferred method of making nanoparticles includes:
a step 50 of providing a microemulsion; a step 52 of providing aqueous solutions of reactants; a step 54 of adding the aqueous solutions to separate aliquots of the microemulsion;
a step 56 of mixing the aliquots to form a reaction mixture that produces nanoparticle cores; and a step 58 of adding a coating agent to the cores to fonn coated nanoparticles.
The microemulsion of step 50 can be made by mixing together at least two immiscible liquids in the presence of at least one surfactant to form a thermodynamically stable, optically isotropic dispersion of nanosize droplets of one or both liquids in the other.
The dispersion is stabilized by the surfactant reducing the surface tension at the interface of the two liquids.
Microemulsions can be either water-in-oil (i.e., reverse micelles or water droplets dispersed in oil), oil-in-water (i.e., micelles or oil droplets dispersed in water), or a bi-continuous system containing coinparable ainounts of two iinmiscible fluids. In some cases, microemulsions can be made by mixing togetller two non-aqueous liquids of differing polarity with negligible mutual solubility. For use in the invention water-in-oil inicroemulsion are presently preferred because they are compatible with very many lcnown chemical reactions for precipitating solids in aqueous solutions.
The immiscible liquids that can be used in step 50 typically include a relatively polar (i.e., hydrophobic) liquid and a relative non-polar (i.e., hydrophillic) liquid. While a large variety of polar/nonpolar liquid mixtures can be used to form a microemulsion useful in the invention, the choice of particular liquids utilized will depend on the type of nanoparticles being made. A skilled artisan can select specific liquids for particular applications by adapting known methods of making microemulsions for use in the present invention. The presently preferred relatively polar liquid is water, although other polar liquids might also be useful. Water is preferred because it is inexpensive, readily available, non-toxic, easy to handle and store, compatible with a large number of different precipitation reactions, and immiscible in a large number of nonpolar solvents. Examples of suitale non-polar liquids include alkanes (e.g., any liquid form of hexane, heptane, octane, nonane, decane, undecane, dodecane, etc.), cycloalkanes (e.g., cyclopentane, cyclohexane, etc.), aromatic hydrocarbons (e.g., benzene, toluene, etc.), and mixtures of the foregoing (e.g., petroleum and petroleum derivatives). In general, any such non-polar liquid can be used as long as it is compatible with the other components used to forin the microemulsion and does not interfere with the involved precipitation reaction.
Step 50 requires at least one surfactant to form a microemulsion. Surfactants are surface active agents that thermodynamically stabilize the very small dispersed micelles or reverse micelles in inicroemulsions. Typically, surfactants possess an amphipathic structure that allows them to form films with very low interfacial tension between the oily and aqueous phases. Thus, any substance that reduces surface tension at the interface of the relatively polar and relatively non-polar liquids and is compatible with other aspects of the invention can be used to form the microemulsion used to make nanoparticles. The choice of a surfactant will depend on the particular liquids utilized and on the type of nanoparticles being made.
Specific surfactants suitable for particular applications can be selected from known methods of making microemulsions or known characteristics of surfactants. For example, non-ionic surfactants are generally preferred when an ionic reactant is used in the microeinulsion process and an ionic detergent would bind to or otherwise interfere with the ionic reactant.
Numerous suitable surfactants are known. A nonexhaustive list includes soaps such as potassium oleate, sodium oleate, etc.; anionic detergents such as Aerosol OT, sodium cholate, sodium caprylate, etc.; cationic detergents such as cetylpyridynium chloride, alkyltrimethylammonium bromides, benzalkonium chloride, cetyldimetllyletliylammonium bromide, etc; zwitterionic detergents such as N-allcyl-N,N-dimethylammonio-1-propanesulfonates and CHAPS; and non-ionic detergents such as polyoxyethylene esters, polyoxyethylene ethers, polyoxyetliylenesorbitan esters, sorbitan esters, and various tritons (e.g., (TX-100, TX-114); etc.
The concentration of surfactant used in step 50 will depend on many factors including the particular surfactant selected, liquids used, and the type of nanoparticles to be made.
Suitable concentrations can be determined empirically, i.e., by trying different concentrations of surfactant until the concentration that performs best in a particular application is found.
Ranges of suitable concentrations can also be determined from known critical micelle concentrations.
In preferred embodiments bis (2-ethylhexyl) sulfosuccinate sodium salt (Aerosol OT, AOT ) is used to create a microeinulsion of water and isooctane;
cetyltrimethylanuiuionium bromide (CTAB) is used to create a microemulsion of n-hexane, n-hexanol, and water; and triton X- 100 (TX- 100) is used to make a microemulsion of cyclohexane, n-hexanol, and water.
Although, in most applications the invention, step 50 employs only one surfactant to stabilize the microemulsion, one or more cosurfactants can also be used. The use of a cosurfactant is sometimes advantageous for stabilizing reverse micelle systems. For example, adding an aqueous surfactant such as soap to a mixture of oil and water yields a milky emulsification. Adding a co-surfactant such as an alcohol of intermediate chain length causes the milky emulsion to clear spontaneously due to formation of very small spheres of dispersed water droplets in oil. Such cosurfactants function by fi,irther reducing the interfacial tension between the phases to facilitate the forination of very small particles of dispersed phase. Suitable co-surfactants for use in the invention include hexanol, butanol, pentanol, octanol, and like intermediate chain length alcohols.
The microemulsion of step 50 is prepared by simply mixing together a relatively polar liquid, a relatively non-polar liquid, and one or more surfactants. For preparing a water-in-oil microemulsion (having aqueous reverse micelles), the volume of the relatively non-polar liquid vastly exceeds that of the relatively polar liquid (e.g., non-polar liquid:polar liquid voluine ratio between about 10000:1 to 100:1). While addition of the surfactant can sometimes cause a microemulsion to form without further agitation, generally the mixture is mechanically (e.g., magnetically) stirred or ultrasonicated to form the microemulsion. Many microemulsions useful in the invention can be prepared at room temperature (i.e., about 20 C) without addition of heat. In other cases, to hasten microemulsion formation by increasing the solubility of the surfactant in the liquids, the mixture of ingredients is sometimes heated (e.g., using a hot plate) to between about 25-80 C.
Referring again to FIG.2, step 52 of providing aqueous solutions of reactants and step 54 of adding the aqueous solutions of step 52 to separate aliquots of a microemulsion can be performed using a water-in-oil microeinulsion prepared as described above.
Steps 52 and 54 can be accomplished by first providing a first water-soluble reactant (reactant A) and a second water-soluble reactant (reactant B), and then adding reactant A to a first aliquot of a water-in-oil microemulsion and reactant B to a second aliquot of a water-in-oil microemulsion. The two aliquots are separately mixed until reactant A reaches equilibrium distribution in each reverse niicelle (reverse micelles continuously form, coalesce, and break apart in the microemulsion, thereby allowing any reactant contained therein to be distributed equally among the reverse micelles) of the first aliquot, and reactant B reaches equilibrium distribution in each reverse micelle of the first aliquot. In step 56, after allowing for the distribution of the dissolved species to equilibrate, the two aliquots are mixed together. Due to collision and coalescence of the reverse micelles, the cations of reactant A and anions of reactant B contact each other and react to form precipitates that serve as nanoparticle cores.
Reactants A and B are generally selected so that they can react to form a precipitate within the reverse micelles of the microemulsions. They are typically soluble in the aqueous reverse micelles and may be solids, liquids, or gases. In a preferred embodiment, Reactant A
is a salt (e.g., with the hypothetical formula A+X") that dissolves into soluble cations (e.g., A+'s) within the reverse micelles of the first aliquot of the microemulsion, and Reactant B is another salt (e.g., with the hypothetical formula BY-) that dissolves into soluble anions (e.g., Y"'s) within the reverse micelles of the second aliquot of the microemulsion.
The cations of Reactant A and anions of Reactant B are selected so that they form a precipitate (A+Y-)when mixed together in an aqueous solution.
While the foregoing illustrates a preferred method of the invention, other methods for making nanoparticle cores using microeinulsions are also within the invention.
Many of these can be perfonned by making slight modifications to the preferred method just.
described. For example, rather than mixing together two different aliquots of a microemulsion, the core-fonning reaction can be carried out using a single aliquot of a microemulsion. In this case, a reactant can be added to the single aliquot and allowed to dissolve and equilibrate among the reverse micelles of the microemulsion.
Subsequently, a precipitating (e.g., reducing or oxidizing) agent in the form of a liquid or gas (e.g., hydrogen, hydrazine, NH4OH) is added to the single aliquot to precipitate the reactant dissolved in the reverse micelles.
Nanoparticle cores can be isolated from a microemulsion by adding a solvent such as acetone or ethanol to the microemulsion and then filtering and/or centrifuging the mixture to isolate the nanoparticles. For filtering, filters have pores sized smaller than the nanoparticles.
For centri-fuging, the mixture can be spun at 10,000 RPM or more in a microcentrifuge for 15 minutes or more to pellet the nanoparticles and the supernatant can be decanted.
Nanoparticles isolated in this manner can be washed one or more times with acetone or an ethanol/water solution to remove any surfactant or other microemulsion component. The isolated and washed nanoparticles can be dried over acetone. Prior to use or functionalization, the nanoparticles can be resuspended in an appropriate liquid.
Using the water-in-oil microemulsion technique, nanoparticle core size is highly controllable. Althougli core size generally relates to reverse micelle size, this is not necessarily a strict relationship as core size does not always correlate with the amount of reactant(s) originally present in each reverse micelle. For example, even small nanoparticle cores (e.g., having diameters of 2 nm to 5 nm) contain from about 300 to 1000 atoms, which is in most cases appreciably larger than the number of reactant molecules present in each micelle prior to reaction. This indicates that nanoparticle core nuclei first form in a small fraction of micelles; these then consume the reactant(s) in other micelles through collision-coalescence processes.
A factor to consider in nanoparticle core preparation therefore is the rate at which nanoparticle cores form. The rate at wliich nanoparticle cores form directly relates to the rate at which the reverse micelles coalesce. Thus, the specific surfactant selected strongly influences the core formation rate, controlling the rate of reverse micelle coalescence. That is, surfactants that result in a relatively rigid interface between the two immiscible liquids of the microemulsion decrease the core formation rate, while surfactants that result in a fluid interface increase the rate. Other properties of the microemulsion, such as ionic strength, pH, and temperature can also be manipulated to control the rate of core formation.
Through empirical adjustment of initial reactant concentrations and microemulsion compositional parameters, nanoparticle cores with homogeneous size distribution (e.g., percentage standard deviation in core size is between about 1 and 5% (for instance, 1, 2, 3, 4, and 5%)) and average diaineters ranging from about 1 nm to about 300 nm or more. Cores of larger size (e.g., about 1 micron) can be prepared by: (i) adding a higher concentration of reagent(s) to the reaction medium (e.g., reverse micelles of the microemulsion), and/or (ii) sonochemically (i.e., by ultrasonication) dispersing isolated cores in a suitable solvent other than microemulsion to make a uniform core suspension, and then adding additional reagent to the dispersion. In the latter method, individual cores often fuse.
In most cases, nanoparticle cores made according to the water-in-oil microemulsion technique described above have a spheroid shape (conventional reverse micelles are spheroid). By altering various parameters in the core formation process, it is possible to produce cores having other shapes. For example, oblong or tube-shaped cores can be made by adding very high concentration of sodium dodecyl sulfate to the microemulsion. As another example, where reactants are selected such that the formed cores have a crystalline structure, nanoparticle cores having a regular or irregular polyhedral shape can be made.
Magnetic nanoparticles can be made using magnetic materials such as magnetite, maghemite, and greigite as part of the core. By varying the overall size and shape of such magnetic cores, they can be made superparamagnetic or stable single-domain (particles that retain a stable magnetic moment after being removed from a magnetic field).
Core size relates to whether a magnetic nanoparticle is superparamagnetic or single-domain.
Thus, relatively equidimensional superparamagnetic particles generally have a core sized less than 50 to 80 nm. At particle sizes above this upper range, the magnetization of the particle is split into domains of differing magnetization vectors in order to minimize internal magnetic energies.
Referring once again to FIG. 2, methods of making nanoparticles within the invention feature a step 58 of adding a coating agent to form coated nanoparticles. The coating agent used in step 58 can be any that causes silica (or another substance) to be deposited onto the surface of the nanoparticle cores. Presently preferred reagents include reactive silicates such as tetraethylorthosilicate (TEOS) or aminopropyltrimethoxysilane (APTS) (both available from Sigma, St. Louis). To coat cores, such reactive silicates are simply added to a solution of nanoparticle cores (e.g., the microemulsion in which the cores were prepared) along with a reducing agent such as aminonium hydroxide or NaOH. The mixture can be stirred for a suitable amount of time to allow the cores to become coated with silica.
Thickness of the silica coating, and the reaction rate for the formation of silica coating are dependent on the amount of reactive silicate added, reaction time, amount of reducing agent added, and reverse micelle size (wliere coating is performed in a water-in-oil microemulsion). Increasing the concentration of the reducing agent (e.g, [NH4OH]) to reactive silicate concentration (e.g., [TEOS]) generally results in a thiclcer coating forming after a given reaction time. Increasing the concentration of polar liquid (e.g., water) to reactive silicate concentration generally results in a thinner coating forming after a given reaction time. The precise reaction conditions for controlling the thickness of the coating will vary according to the particular agent used, the core material, etc. These, however, can be deteimined empirically by simple experiments varying the concentrations of reagents and reaction times and conditions.
Methods within the invention can also include a step of functionalizing (i.e., derivatizing with one or more functional chemical groups) coated nanoparticles made as described above. Numerous known methods for attaching functional groups to silica can be adapted for use in the present invention. See, e.g., Ralph K. Iler, The Chemistry of Silica:
Solubility, Polymerization, Colloid and Surface Properties, and BiochemistrY, Wiley-Interscience, NY, 1979; VanDerVoort, P. and Vansant, E. F., Journal of Liquid Chromatography and Related Technologies, 19:2723 -2752, 1996; and Immobilized Enzymes, Antigens, Antibodies, and Peptides: Preparation and Characterization, Howard H. Weetall (ed.), M. Dekker, NY, 1975. A typical process for adding functional groups to silica-coated nanoparticles involves treating the nanoparticles with a silanizing agent that reacts with and couples a chemical group to the silica surface of the nanoparticles. The chemical group can itself be the functional group, or it can serve as a substrate to which functional groups can be coupled.
For example, in an exemplary method, silica-coated nanoparticles are prepared as described above and the particle surfaces are silanized using trimethylsilylpropyl-diethylenetriamine (DETA), a silanization agent that attaches primary amine groups to silica surfaces. Antibodies or other proteins can then be covalently coupled to the silanized surface using the cyanogen bromide (CNBR) method. As one example, CNBR-mediated coupling can be achieved by suspending silica-coated nanoparticles previously silanized with DETA in a 2 M sodium carbonate buffer and ultrasonicating the mixture to create a particle suspension.
A solution of CNBR (e.g., 2 g CNBR/1 ml acetonitirile) is then added to the particle suspension to activate the nanoparticles. After washing the nanoparticles with a neutral buffer (e.g., PBS, pH 8), an antibody solution is added to the activated nanoparticle suspension causing the antibodies to become bound to the nanoparticles. A
glycine solution can also be added to the antibody-coated nanoparticles to block any remaining unreacted sites.
Methods of Using Nanoparticles Nanoparticles of the invention to isolate cells (e.g., eukaryotic or prokaryotic cells).
One such method is illustrated in FIG. 3. Referring to FIG. 3A, antibody-derivatized magnetic nanoparticles 10 are shown mixed with target cells 20 and non-target cells 21 in container 30. Target cells 20 express a target antigen 22 on their surface, while non-target cells 21 do not. In the nanoparticles shown, core 12 includes a ferrous material such as magnetite or maghemite, and functional groups 16 include an antibody that can specifically bind target antigen 22. Referring now to FIG. 3B, nanoparticle 10 is shown physically binding target ce1120 via the interaction of functional groups 16 and target antigen 22. Such binding spontaneously results when nanoparticle 10 and target cel120 are mixed together in container 30 under conditions which allow antibody-antigen binding (e.g., about room temperature, neutral to slightly basic pH in a low salt buffer). Non-target cells 21 do not specifically bind nanoparticles 10 because they do not express target antigen 22. As shown in FIG. 3C, application of a magnetic field to the nanoparticle-cell mixture by insertion of magnet 32 into container 30 causes nanoparticles 10 and bound target cells 21 to associate with magnet 32. Referring to FIG. 3D, by removing magnet 32 from container 30, target cells 20 can be isolated. Cells 20 can be separated from nanoparticles 10 using an excess of soluble antigen.
Many other applications are specifically envisioned including, for example, cell labeling (see Exaiuple 8 below), targeted drug or gene delivery, biosensors, magnetic recording media, magnetic resonance imaging, and use in micro- or nano-sized machines.
For example, cytotoxic drugs or viral vectors carrying therapeutic genes can be attached to the functional groups on the surface of nanoparticles. These nanoparticles can then be dispersed in a pharmaceutically acceptable carrier (e.g., USP grade saline) and administered to a patient (e.g., by intravenous injection). Magnetic fields can then be used to concentrate the virus or drug at the delivery site to enhance site-specific uptalce (e.g., by placing a magnet at the site).
Drugs coated onto nanoparticles can be further contained witliin a time-release coating (e.g., a biodegradable sugar) so that the drug can accuinulate at the site before becoming active.
In other envisioned examples, fluorescence-based biosensors can be attached to the particles. The resulting particles can be manipulated by magnetic means into specific target sites (specific locations in isolated cells), and used to monitor biochemical processes in situ.
The nanoparticles of the invention are also thought to be useful for enhancing Magnetic Resonance Images (MRI). For example, as described above, antibody or ligand-coated nanospheres can be caused to accumulate at sites in the body where the target antigen or receptor is concentrated or located. In comparison to non-targeted MRI
contrast agents, the increased concentration of particles at a targeted site will enhance the contrast in an MRI.
Nanoparticles manufactured in a stable, single domain size range that allows a remnant magnetization to be preserved are envisioned to be useful in binary magnetic recording applications where they can be substituted for the simple iron particles used in conventional magnetic storage devices. For example, arrays of ferrite-doped silica particles could be tailored for minimum magnetostatic interactions to permit individual nanoparticles to be magnetized either parallel or antiparallel to their easy axis of magnetization for binary data storage applications. And because stable single domain particles are able to transduce applied magnetic fields as mechanic motion (i.e. a torque can be exerted on the particle when a magnetic field is applied at an angle to the easy axis of magnetization), arrays of these nanoparticles of the invention could find use as mechanical micro- or nanomachines. One particular example would be micromechanical gate activation upon application of an external magnetic field.
Examples Exainple 1-Preparation of Silica-Coated Magnetite Nanoparticles by Microemulsion:
(A) A 0.27 M bis (2-ethylhexyl) sulfosuccinate sodium salt (Aerosol OT or AOT
) solution was prepared by dissolving 12 g AOT in 10 ml isooctane. An aliquot of ultra-pure water was purged for one hour wit11 Nz gas. A stock solution of 1 M Fe(II) was prepared by dissolving 0.278 g FeSO4 7H20 in 1 ml of the nitrogen purged water. Similarly, a stock solution of 1.5 M Fe(III) was prepared by dissolving 0.4055 g FeC13'6 H20 (0.4055 gm) in 1 ml of the nitrogen purged water. In a glass container, 25 1 of the 1 M Fe(II) solution and 25 l of the 1.5M Fe(III) solution were added to a 5 ml aliquot of the AOT
solution under a nitrogen atmosphere, and the resulting Fe/AOT mixture was magnetically stirred for 1 hr to form a Fe/AOT solution. In another container, 100 l NH4OH (28-30 wt%) was added to another 5 ml aliquot of the AOT solution, and the resulting NH¾OH/AOT mixture was magnetically stirred for 1 hr to form a NH4OH/AOT solution. In absence of magnetic field, the NH4OH/AOT solution was added dropwise to the Fe/AOT solution with vigorous mechanical stirring for 1 hr. Initially a light yellow solution formed. This solution turned brown (without any precipitate formation) as magnetite nanoparticles formed.
50 l of tetraethylorthosilicate (TEOS) was then added to the resulting brown solution and mechanical stirring was continued for an additional 24 hrs. Silica-coated unifomz-sized nanoparticles in powder form were obtained by coagulating the colloidal microemulsion with acetone, and then filtering and washing the particles with acetone and ethanol several times with each solvent. In some cases, 50% (v/v) solution of ethanol/water was also used for washing.
(B) 1.78 g of AOT was dissolved in 20.0 ml of isooctane. The resulting solution was mixed using a sonicator and flushed with nitrogen. 100 L each of Nz flushed 0.10 M
FeSO4 and 0.15 M FeC13 (both prepared in water) were then added and mixed into the solution to form a microemulsion. 100 L of N2-flushed solution of 2.0 M NaOH
was then added, and the resulting microemulsion was sonicated for 1 hour while being continuously flushed with N2. 10 L of TEOS was then added to the sonicated microemulsion, and the mixture was allowed to react overnight. The isooctane contained in the microemulsion was then evaporated and the remaining gel was dissolved in ethanol. This solution was centrifuged to pellet the nanoparticles and the supernatant was discarded.
After washing 3 or 4 more times with ethanol, the resulting nanoparticles were subjected to TEM
which showed that nanoparticles having a diameter of approximately 3-5 nm were produced. A
silica shell was observed as a translucent halo, about 2-3 nin tllick surrounding the denser core.
(C) A microemulsion I (ME I) was prepared by first dissolving 8.89 g AOT in 40.0 ml isooctane to form a first solution. 1.2 ml H20 and 6.0 ml FeSO4 was then added and the mixture was sonicated to form ME I. In another glassware, a microemulsion II (ME II) was similarly prepared by first dissolving 8.89 g AOT and dissolve in 40.0 ml isooctane to form a second solution. 3.2 ml H20 and 4.0 ml NH4OH was added to the second solution, which was then mixed for about 30 minutes to form ME II. 10 L TEOS was added to ME
II, and the mixture was allowed to react for about 2 hours. Using a glass syringe, ME II was slowly added to ME I, and the reaction mixture thus formed was sonicated for 24 hours. As described in (B) above, the isooctane was then evaporated, the remaining gel was dissolved in ethanol and centrifuged to recover the formed nanoparticles which were washed 3 or 4 times with additional ethanol. TEM showed that nanoparticles having a diameter of approximately 25 nm were produced. A silica shell was observed as a translucent halo about 5 nm thick surrounding the denser core.
Example 2- Preparation of Dye-doped Silica-Coated Nanoparticles (A) Preparation of Eu/Bpy (Eu3+/2,2'-dipyridyl)-doped silica nanoparticles in cetyltrimethylammonium bromide (CTAB)/n-hexane/n-hexanol (cosurfactant)/water water-in-oil microemulsions. 90 ml of a water-in-oil microemulsion stock solution was prepared by mixing together 2.916 g CTAB, 75 ml n-hexane, 15 ml n-hexanol and 880 l water using a magnetic stirrer. 10 ml of the stock solution was equally divided into two 5 ml aliquots. 50 l T'EOS and 5 10.1 M Eu/Bpy (aqueous solution) was added to one of the 5 ml aliquots and the mixture was stirred for 1 hr to form a TEOS/Eu/Bpy solution. 137 l NH¾OH
was added to the other 5 ml aliquot and the mixture was stirred for 1 hr to form an NH4OH solution.
The NH4OH solution was then added dropwise to the TEOS/Eu/Bpy solution and the resulting mixed solution was stirred overnight. The water to surfactant molar ratio of the mixed solution was 15 (water:surfactant). Eu/Bpy-doped silica nanoparticles were isolated in powder form by adding 25 ml of acetone to the microemulsion of the mixed solution, centrifuging the resultant mixture for 15 minutes at 10,00RPM in a microcentrifuge to pellet the nanoparticles, the supernatant was removed and the remaining nanoparticles were washed several times with acetone or an etlianol/water solution to further remove surfactant and other microemulsion components. The washed nanoparticles were then dried over acetone.
(B) Ru/Bpy [RuII(Bpy)3]-doped silica nanoparticles in triton X-100 (TX-100)/
cyclohexane/n-hexanol(cosurfactant)/water water-in-oil microemulsions. 10 ml of a water-in-oil microemulsion was prepared by mixing 7.5 ml cyclohexane, 1.8 ml n-hexanol, 1.77 ml TX-100, 340 l water and 140 10.1 M RuII(Bpy)3 (aqueous solution) for 1 hr with a magnetic stirrer. The resulting solution was then divided into two 5 ml aliquots. 100 1 TEOS was added to one aliquot and the mixture was stirred for 30 minutes to form a TEOS
solution. 60 l of NH4OH was added to the other 5 ml aliquot and the mixture was stirred for 30 minutes to form a NH¾OH solution. The NH4OH solution was then added to the TEOS
solution dropwise for a period of 10 minutes and the resulting mixed solution was stiiTed overnight. Ru/Bpy doped silica nanoparticles were isolated as described above in (A).
Exainple 3- Preparation of Metal-Doped Silica-Coated Nanoparticles ml of a TX-100/cyclohexane/n-hexanol(cosurfactant)/waterwater-in-oil microemulsion stock solution was prepared as described in Example 2(A). The stock solution was equally divided into two 5 ml aliquots. 30 l of a 1M aqueous solution of silver nitrate (AgNO3) was added to one of the 5 ml aliquots and the mixture was stirred for about 30 minutes to form a AgNO3 solution. 11 l of a 2M aqueous solution of sodium borohydride (NaBH4) was added to the other 5 ml aliquot and the mixture was stirred for about 30 minutes to form an NaBH4 solution. The NaBH¾ solution was then added dropwise to the AgNO3 solution for the period of 15 minutes to form a reaction mixture.
After 5 minutes, 10 l of TEOS was added and the resulting mixture stirred for another 15 minutes.
l of a NH4OH solution was then added and stirring was continued overnight. The Ag-doped silica nanoparticles were isolated similar to the procedure described in Example 2(A), i.e., by adding 25 ml of acetone to the microemulsion, filtering, washing several times with an ethanol/water solution to remove surfactant, and finally drying over acetone.
Using a variation of this method cadmiuin sulfide (CDs)-doped silica nanoparticles were also prepared. In this case, cadmium nitrate and ammonium sulfide were used in place of silver nitrate and sodium borohydride, respectively.
Example 4- Preparation of Pi ments A new class of piginents was prepared using regular inorganic salts including potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, and copper nitrate. While these salts are highly water soluble, they become completely insoluble when coated with silica, and thus behaved as pigments.
All were colored and photostable.
These pigments was prepared as described for the Ru/Bpy doped silica nanoparticles described above in Example 2(B), except that a 0.1M salt solution (e.g., potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, and copper nitrate) was used in place of the 0.1 M Ru'I(Bpy)3 solution, and an additional 100 l TEOS and 60 l NH4OH were added to the mixed solution 12 hrs after the 10 ul addition of NH4OH. Pigment particles were separated from the mixture after 24 hrs.
Example 5- Characterization of Nanoparticles Transmission electron microscopy (TEM) and other analyses were used to characterize of the size of various nanoparticles made according to the invention. As one exainple, RuII(Bpy)3 nanoparticles were prepared as described in Example 2(B) and subjected to TEM. By analyzing photographs of the TEM images, it was deterinined that the RuII(Bpy)3 nanoparticles had a core size of about 20 nm (standard deviation= +/-2 nm) and an overall particle size of about 100 nm (standard deviation= +/-10 nm). Smaller and larger silica-coated nanoparticles were also prepared by varying the preparation conditions specified above. For example, those with core sizes even as small as 2 nm (e.g., sized to prepare quantum dots) with constant or varied thickness (as large as 300 nm) of the outer silica coating have been prepared. Nanoparticles useful as pigments (see Example 5) were also subjected to TEM which showed that such particles were sized between 0.2 and 0.3 m. In other analyses, compared to commercially available conventional dyes, dye-doped nanoparticles made according to the invention proved extremely resistant to bleaching even after strong excitation from a laser source. Similarly, no fluorescence quenching was observed in fluorescent dye-doped nanoparticles.
Example 6- Preparation of a Nanoparticle-based Chemosensor Dye-doped, silica-coated nanoparticles were prepared using a water-in-oil microemulsion technique. The water-in-oil microemulsion was prepared first by mixing Triton X- 100 (TX- 100), cyclohexane, n-hexanol (4.2:1:1 VN) and an adequate amount of water. An aqueous dye solution (RuII(Bpy)3; (see example 3B above) was then added to the microemulsion in such a way that the water to surfactant molar ratio was kept constant at 10.
The final dye concentration in the mixture was 0.1 M. TEOS was then added to the mixture.
A polymerization reaction was initiated by adding NH4OH (volume ratio of TEOS
to NH¾OH
was 1.7), and the reaction was allowed to continue for 12 hours. After the reaction was complete, the dye-doped silica nanoparticles were isolated by adding acetone to the reaction, followed by centrifuging and washing with ethanol and water for several times.
The nanoparticles were then stored in aqueous solution for later usage.
The dye-doped silica nanoparticles produced were uniform in size, as characterized by transmission electron microscopy (TEM) and atomic force microscopy (AFM). A
TEM
image of the dye-doped silica particles showed that the particles were 60 10 nm in size and uniform. At a higher resolution, the luininescent complex of RuBpy dye aggregates were also visible as darker dots embedded inside the silica sphere due to the presence of heavy metal atom in these dye molecules. These individual dye aggregates were as small as 1 nm.
To investigate whether the RuBpy molecules doped inside the silica network could function as an oxygen sensor, the fluorescence emission spectra of free RuBpy molecules was coinpared to that of the RuBpy-doped nanoparticles at various air pressures.
With the free RuBpy dye molecules, the intensity of the emission was greatly decreased as the air pressure was increased from 1 to 14 psi. In contrast, under the same conditions, no significant change in the emission spectra for the dye-doped silica-coated nanoparticles was observed, indicating that the silica network was essentially impermeable to oxygen molecules. In other experiments, the dye-doped silica-coated nanoparticles also showed excellent photostability even upon intensive laser illumination.
Example 7- Functionalized Silica-Coated Nanoparticles The dye-doped, silica-coated nanoparticles of Example 6 were derivatized with antibodies by first silanizing the particle surfaces with DETA, a silanization agent that attaches the primary amine group to silica surfaces. Using fluorescamine, a non-fluorescent molecule that becomes highly fluorescent upon reacting with the primary aliphatic amine group (Cordek, J. Wang, X and Tan W., Anal Chein, 71, 1529-1533, 1999; Chung, L. A. Anal Biochem. 1997,248,195), the presence of amine group on the surface of the nanoparticles was confirmed.
After surface silanization with DETA, an antibody (mouse anti-human CD 10) was immobilized onto the silanized silica surface using the cyanogen bromide (CNBR) method.
Dye-doped particles (26 g) were prepared as described in Example 6, dried, and then suspended in 9.0 m12 M sodium carbonate solution (activation buffer) using ultrasonication.
A solution of CNBR in acetonitrile (1.0 gm of CNBR dissolved in 0.5 ml acetonitrile) was then added dropwise to the particle suspension (10 mg/ml) under stirring for 5 minutes at room teinperature. The resulting CNBR-activated particles were washed twice with ice-cold water and twice with PBS buffer (pH 8.0).
40 l of the antibody diluted in PBS buffer (pH 8.0) was then added to the surface modified particles, and stirring was continued for 24 hours at 4 C. The resulting antibody-derivatized nanoparticles were then treated with 10 ml of 0.03 M glycine solution for 30 minutes to block any remaining reactive sites. The final product was washed, re-suspended in PBS (pH 8.0) buffer and stored at 4 C for future usage. No change in the optical and spectroscopic properties of the nanoparticles was observed.
Example 8-Cell Labeling Mononuclear lymphoid cells (about 2 million cells/ml) were obtained as a suspension in the cell culture medium. The cell suspension was incubated for 2 hours with the anti-CD 10 immobilized nanoparticles described in Exainple 7. After incubation, the cell suspension was imaged with both optical microscopy and fluorescence microscopy. The microscopic analysis revealed that most of the cells were labeled (indicated by the bright emission of the dye-doped particles). The optical images correlated well with the fluorescence images. In control experiments using non-antibody derivatized dye-doped nanoparticles, no labeling of cells was observed. In the labeled cells, the signal-to-noise ratio (i.e., the ratio between the intensities of the bright and the darlc areas in the fluorescence image) was over 500.
Other Embodiments While the above specification contains many specifics, these should not be construed as limitations on the scope of the invention, but rather as exainples of preferred embodiments tliereof. Many other variations are possible. Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their legal equivalents.
Claims (111)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A plurality of nanoparticles having a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising a pigment and (b) a silica shell enveloping the core, wherein the pigment is an inorganic salt that is potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron(III) chloride, or copper nitrate.
2. The plurality of nanoparticles of claim 1, wherein the mean size is between 1 nm and 300 nm.
3. The plurality of nanoparticles of claim 1, wherein the mean size is between 2 nm and 10 nm.
4. The plurality of nanoparticles of claim 1, wherein the silica shell is derivatized with a functional group.
5. The plurality of nanoparticles of claim 4, wherein the functional group is a protein.
6. The plurality of nanoparticles of claim 5, wherein the functional group is an antibody.
7. The plurality of nanoparticles of claim 4, wherein the functional group is a nucleic acid.
8. The plurality of nanoparticles of claim 4, wherein the functional group is a substance that is biotin or streptavidin.
9. A plurality of nanoparticles having a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising a dye, and (b) a silica shell enveloping the core.
10. The plurality of nanoparticles of claim 9, wherein the dye is Ruthenium-tris(2,2'-bipyridyl)dichloride or Europium-bis(2,2'bipyridyl)trichloride.
11. The plurality of nanoparticles of claim 9, wherein the mean size is between 1 nm and 300 nm.
12. The plurality of nanoparticles of claim 9, wherein the mean size is between 2 nm and 10 nm.
13. The plurality of nanoparticles of claim 9, wherein the silica shell is derivatized with a functional group.
14. A The plurality of nanoparticles of claim 13, wherein the functional group is a protein.
15. The plurality of nanoparticles of claim 13, wherein the functional group is an antibody.
16. The plurality of nanoparticles of claim 13, wherein the functional group is a nucleic acid.
17. The plurality of nanoparticles of claim 13, wherein the functional group is a substance that is biotin or streptavidin.
18. A plurality of nanoparticles having a mean size of between 2 nm and 10 nm, each of said nanoparticles comprising (a) a core comprising a metal and (b) a silica shell enveloping the core.
19. The plurality of nanoparticles of claim 18, wherein the core is magnetic.
20. The plurality of nanoparticles of claim 19, wherein the core is superparamagnetic.
21. The plurality of nanoparticles of claim 19, wherein the core has a fixed magnetic moment.
22. The plurality of nanoparticles of claim 18, wherein the core has a spherical shape.
23. The plurality of nanoparticles of claim 18, wherein the core has an oblong shape.
24. The plurality of nanoparticles of claim 18, wherein the core has a tube-like shape.
25. The plurality of nanoparticles of claim 18, wherein the metal is magnetite.
26. The plurality of nanoparticles of claim 18, wherein the metal is maghemite.
27. The plurality of nanoparticles of claim 18, wherein the metal greigite.
28. The plurality of nanoparticles of claim 18, wherein the silica shell is derivatized with a functional group.
29. The plurality of nanoparticles of claim 28, wherein the functional group is a protein.
30. The plurality of nanoparticles of claim 28, wherein the functional group is an antibody.
31. The plurality of nanoparticles of claim 28, wherein the functional group is a nucleic acid.
32. The plurality of nanoparticles of claim 28, wherein the functional group is biotin or streptavidin.
33. A plurality of nanoparticles having a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising a metal and (b) a silica shell enveloping the core, wherein the size distribution of the nanoparticles has a standard deviation of no more than 25 percent.
34. The plurality of nanoparticles of claim 33, wherein the core is magnetic.
35. The plurality of nanoparticles of claim 34, wherein the core is superparamagnetic.
36. The plurality of nanoparticles of claim 34, wherein the core has a fixed magnetic moment.
37. The plurality of nanoparticles of claim 33, wherein the core has a spherical shape.
38. The plurality of nanoparticles of claim 33, wherein the core has an oblong shape.
39. The plurality of nanoparticles of claim 33, wherein the core has a tube-like shape.
40. The plurality of nanoparticles of claim 34, wherein the metal is magnetite.
41. The plurality of nanoparticles of claim 34, wherein the metal is maghemite.
42. The plurality of nanoparticles of claim 34, wherein the metal greigite.
43. The plurality of nanoparticles of claim 33, wherein the silica shell is derivatized with a functional group.
44. The plurality of nanoparticles of claim 43, wherein the functional group is a protein.
45. The plurality of nanoparticles of claim 43, wherein the functional group is an antibody.
46. The plurality of nanoparticles of claim 43, wherein the functional group is a nucleic acid.
47. The plurality of nanoparticles of claim 43, wherein the functional group is a substance that is biotin or streptavidin.
48. The plurality of nanoparticles of claim 33, wherein the core consists of metal and each of the nanoparticles comprises a structure consisting of the core enveloped by the silica shell.
49. The plurality of nanoparticles of claim 33, wherein the mean size is 10 nm.
50. The plurality of nanoparticles of claim 33, wherein the mean size is 15 nm.
51. The plurality of nanoparticles of claim 33, wherein the mean size is 20 nm.
52. The plurality of nanoparticles of claim 33, wherein the mean size is 25 nm.
53. The plurality of nanoparticles of claim 33, wherein the mean size is 30 nm.
54. The plurality of nanoparticles of claim 33, wherein the mean size is 35 nm.
55. The plurality of nanoparticles of claim 33, wherein the mean size is 50 nm.
56. A plurality of nanoparticles having a mean size of less than 1 micron, each of said nanoparticles comprising (a) a core comprising Ag, and (b) a silica shell enveloping the core.
57. The plurality of nanoparticles of claim 56, wherein the mean size is between 1 nm and 300 nm.
58. The plurality of nanoparticles of claim 56, wherein the mean size is between 2 nm and 10 nm.
59. The plurality of nanoparticles of claim 56, wherein the silica shell is derivatized with a functional group.
60. The plurality of nanoparticles of claim 59, wherein the functional group is a protein.
61. The plurality of nanoparticles of claim 59, wherein the functional group is an antibody.
62. The plurality of nanoparticles of claim 59, wherein the functional group is a nucleic acid.
63. The plurality of nanoparticles of claim 59, wherein the functional group is biotin or streptavidin.
64. A method of identifying cells expressing a preselected molecule comprising the steps of:
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising a pigment and a silica shell enveloping the core, wherein the pigment is an inorganic salt that is potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron (III) chloride, or copper nitrate; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture; placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising a pigment and a silica shell enveloping the core, wherein the pigment is an inorganic salt that is potassium permanganate, potassium dichromate, nickel sulfate, cobalt-chloride, iron (III) chloride, or copper nitrate; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture; placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
65. The method of claim 64, wherein the silica-coated nanoparticles are fluorescent.
66. The method of claim 64, wherein the nanoparticles have a mean size between 1 nm and 300 nm.
67. The method of claim 64, wherein the nanoparticles have a mean size between 2 nm and 10nm.
68. The method of claim 64, wherein the functional group is a protein.
69. The method of claim 68, wherein the protein is an antibody that specifically binds to the preselected molecule.
70. The method of claim 64, wherein the functional group is a nucleic acid.
71. The method of claim 64, wherein the functional group is a substance that is biotin or streptavidin.
72. The method of claim 64, wherein the silica shell comprises a reactive silicate that is TEOS (tetraethylorthosilicate) or APTS (aminopropyltrimethoxysilane).
73. A method of identifying cells expressing a preselected molecule comprising the steps of:
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising a dye and a silica shell enveloping the core; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture;
placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising a dye and a silica shell enveloping the core; mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture;
placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
74. The method of claim 73, wherein the silica-coated nanoparticles are fluorescent.
75. The method of claim 73, wherein the nanoparticles have a mean size between 1 nm and 300 nm.
76. The method of claim 73, wherein the nanoparticles have a mean size between 2 nm and nm.
77. The method of claim 73, wherein the dye is Ruthenium-tris(2,2'-bipyridyl)dichloride or Europium-bis(2,2'-bipyridyl)trichloride.
78. The method of claim 73, wherein the functional group is a protein.
79. The method of claim 78, wherein the protein is an antibody that specifically binds to the preselected molecule.
80. The method of claim 73, wherein the functional group is a nucleic acid.
81. The method of claim 73, wherein the functional group is a substance that is biotin or streptavidin.
82. The method of claim 73, wherein the silica shell comprises a reactive silicate that is TEOS (tetraethylorthosilicate) or APTS (aminopropyltrimethoxysilane).
83. A method of identifying cells expressing a preselected molecule comprising the steps of:
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of between 2 nm and 10 nm and comprising a core comprising a metal and a silica shell enveloping the core;
mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture; placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of between 2 nm and 10 nm and comprising a core comprising a metal and a silica shell enveloping the core;
mixing the plurality of silica-coated nanoparticles with the plurality of cells to form a mixture; placing the mixture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
84. The method of claim 83, wherein the core is magnetic.
85. The method of claim 84, wherein the core comprises a metal that is magnetite, maghemite, or greigite.
86. The method of claim 83, wherein the functional group is a protein.
87. The method of claim 86, wherein the protein is an antibody that specifically binds to the preselected molecule.
88. The method of claim 83, wherein the functional group is a nucleic acid.
89. The method of claim 83, wherein the functional group is a substance that is biotin or streptavidin.
90. The method of claim 83, wherein the silica shell comprises a reactive silicate that is TEOS (tetraethylorthosilicate) or APTS (aminopropyltrimethoxysilane).
91. A method of identifying cells expressing a preselected molecule comprising the steps of:
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising Ag and a silica shell enveloping the core; mixing the plurality of silica-coated nanopartides with the plurality of cells to form a mixture;
placing the rruxture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
providing a plurality of cells at least some of which express the preselected molecule;
providing a plurality of silica-coated nanoparticles coated with a functional group that binds to the preselected molecule, each of said nanoparticles having a mean size of less than 1 micron and comprising a core comprising Ag and a silica shell enveloping the core; mixing the plurality of silica-coated nanopartides with the plurality of cells to form a mixture;
placing the rruxture under conditions that allow the nanoparticles to bind to cells expressing the preselected molecule; and analyzing the cells for bound nanoparticles to identify the cells expressing the preselected molecule.
92. The method of claim 91, wherein the nanoparticles have a mean size between 1 nm and 300 nm.
93. The method of claim 91, wherein the nanoparticles have a mean size between 2 nm and 20 nm.
94. The method of claim 91, wherein the functional group is a protein.
95. The method of claim 94, wherein the protein is an antibody that specifically binds to the preselected molecule.
96. The method of claim 91, wherein the functional group is a nucleic acid.
97. The method of claim 91, wherein the functional group is a substance that is biotin or streptavidin.
98. The method of claim 91, wherein the silica shell comprises a reactive silicate that is TEOS (tetraethylorthosilicate) or APTS (aminopropyltrimethoxysilane).
99. A method of making coated nanoparticles comprising the steps of: providing a microemulsion; providing a first aqueous solution of a first reactant and a second aqueous solution of a second reactant, the first reactant and second reactant being selected such that a solid precipitate forms upon mixing the first and second reactants together in an aqueous environment; adding the first aqueous solution to a first aliquot of the microemulsion and the second aqueous solution to a second aliquot of the microemulsion; mixing together the first and second aliquots to form a reaction mixture that reacts to form nanoparticle cores; and adding a coating agent to the cores to form coated nanoparticles.
100. The method of claim 99, wherein the microemulsion is a water-in-oil microemulsion.
101. The method of claim 100, wherein the water-in-oil microemulsion comprises water; a relatively polar liquid that is isooctane, n-hexane or cyclohexane; and a surfactant that is AOT (bis(2-ethylhexyl) sulfosuccinate sodium salt), TX-100 (t-octylphenoxypolyethoxyethanol), or CTAB (cetyltrimethylammonium bromide).
102. The method of claim 101, wherein the water-in-oil microemulsion further comprises a cosurfactant.
103. The method of claim 102, wherein the cosurfactant is n-hexanol.
104. The method of claim 99, wherein the coated nanoparticles are coated with a silica shell.
105. The method of claim 104, wherein the coating agent comprises a reactive silicate that is TEOS (tetraethylorthosilicate) or APTS (aminopropyltrimethoxysilane).
106. The method of claim 104, wherein the silica shell is derivatized with a functional group.
107. The method of claim 104, wherein the functional group is a protein.
108. The method of claim 107, wherein the functional group is an antibody.
109. The method of claim 107, wherein the nanoparticle cores comprise a metal that is magnetite, maghemite, or greigite.
110. The method of claim 104, wherein the functional group is a nucleic acid.
111. The method of claim 104, wherein the functional group is a substance that is biotin or streptavidin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/572,469 | 2000-05-17 | ||
US09/572,469 US6548264B1 (en) | 2000-05-17 | 2000-05-17 | Coated nanoparticles |
PCT/US2001/040729 WO2001088540A1 (en) | 2000-05-17 | 2001-05-14 | Coated nanoparticles |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2410023A1 CA2410023A1 (en) | 2001-11-22 |
CA2410023C true CA2410023C (en) | 2010-03-16 |
Family
ID=24287937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2410023A Expired - Fee Related CA2410023C (en) | 2000-05-17 | 2001-05-14 | Coated nanoparticles |
Country Status (9)
Country | Link |
---|---|
US (3) | US6548264B1 (en) |
EP (2) | EP1287359B1 (en) |
JP (1) | JP2003533363A (en) |
AT (1) | ATE374946T1 (en) |
AU (2) | AU2001261841B2 (en) |
CA (1) | CA2410023C (en) |
DE (1) | DE60130757T2 (en) |
NZ (1) | NZ523078A (en) |
WO (1) | WO2001088540A1 (en) |
Families Citing this family (349)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040200094A1 (en) * | 1996-11-12 | 2004-10-14 | Baychar | Softboots and waterproof /breathable moisture transfer composite and liner for in-line skates, ice-skates, hockey skates, snowboard boots, alpine boots, hiking boots and the like |
US20050034330A1 (en) * | 1996-11-12 | 2005-02-17 | Baychar | Running shoes, hiking shoes and boots, snowboard boots, alpine boots, hiking boots, and the like, having waterproof/breathable moisture transfer characteristics |
BR0014252A (en) * | 1999-09-14 | 2002-11-19 | Biomedical Apherese Systeme Gm | Magnetic nanoparticles having biochemical activity, method for their production and uses |
DE10013670A1 (en) * | 2000-03-20 | 2001-09-27 | Inst Neue Mat Gemein Gmbh | Process for separating at least one component from liquid or gaseous media comprises contacting the medium with a nano composite so that the components to be separated are partially bound with the nano composite |
US6773823B2 (en) * | 2000-04-07 | 2004-08-10 | University Of New Orleans Research And Technology Foundation, Inc. | Sequential synthesis of core-shell nanoparticles using reverse micelles |
US6548264B1 (en) * | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
ATE425457T1 (en) * | 2000-10-06 | 2009-03-15 | Life Technologies Corp | CELLS WITH A SPECTRAL SIGNATURE AND METHOD FOR THEIR PRODUCTION AND USE |
US20050059031A1 (en) * | 2000-10-06 | 2005-03-17 | Quantum Dot Corporation | Method for enhancing transport of semiconductor nanocrystals across biological membranes |
EP1339865A2 (en) * | 2000-10-11 | 2003-09-03 | Evotec OAI AG | Multiplex assays using nanoparticles |
AU3958102A (en) * | 2000-12-15 | 2002-06-24 | Univ Arizona | Method for patterning metal using nanoparticle containing precursors |
US7553662B2 (en) * | 2000-12-22 | 2009-06-30 | Keele University | Culturing tissue using magnetically generated mechanical stresses |
US7811768B2 (en) * | 2001-01-26 | 2010-10-12 | Aviva Biosciences Corporation | Microdevice containing photorecognizable coding patterns and methods of using and producing the same |
US7015047B2 (en) * | 2001-01-26 | 2006-03-21 | Aviva Biosciences Corporation | Microdevices having a preferential axis of magnetization and uses thereof |
JP5101791B2 (en) * | 2001-04-13 | 2012-12-19 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Superparamagnetic nanostructured material |
US6936181B2 (en) | 2001-10-11 | 2005-08-30 | Kovio, Inc. | Methods for patterning using liquid embossing |
EP1469989B1 (en) * | 2002-01-02 | 2011-12-14 | Visen Medical, Inc. | Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates |
DE10201084A1 (en) * | 2002-01-14 | 2003-07-24 | Bayer Ag | Magnetic particles containing silicon, process for their production and use of the particles |
US7052777B2 (en) * | 2002-02-15 | 2006-05-30 | Nanophase Technologies Corporation | Composite nanoparticle materials and method of making the same |
IL148350A0 (en) * | 2002-02-25 | 2002-09-12 | J G Systems Inc | Processing and repairing emulsions and microemulsions for use in optical fibers |
WO2003089906A2 (en) * | 2002-04-22 | 2003-10-30 | University Of Florida | Functionalized nanoparticles and methods of use |
US7217512B2 (en) * | 2002-05-09 | 2007-05-15 | Corning Incorporated | Reagent and method for attaching target molecules to a surface |
US7670623B2 (en) * | 2002-05-31 | 2010-03-02 | Materials Modification, Inc. | Hemostatic composition |
GB0214209D0 (en) * | 2002-06-19 | 2002-07-31 | Univ Keele | Method |
US20080131648A1 (en) | 2003-06-23 | 2008-06-05 | Solid Water Holdings | Waterproof/breathable, moisture transfer, soft shell alpine boots and snowboard boots, insert liners and footbeds |
DE60316748T2 (en) * | 2002-06-27 | 2008-02-07 | Toyo Boseki K.K. | Magnetic carrier for biological substances, process for its production and its use for the isolation of these biological substances |
GB0215185D0 (en) * | 2002-07-01 | 2002-08-07 | Genovision As | Binding a target substance |
US6957608B1 (en) | 2002-08-02 | 2005-10-25 | Kovio, Inc. | Contact print methods |
US6878184B1 (en) | 2002-08-09 | 2005-04-12 | Kovio, Inc. | Nanoparticle synthesis and the formation of inks therefrom |
US7176036B2 (en) * | 2002-09-20 | 2007-02-13 | Arrowhead Center, Inc. | Electroactive microspheres and methods |
US20040076961A1 (en) * | 2002-10-21 | 2004-04-22 | Lewis Mark A. | Biomolecule retaining material and methods for attaching biomolecules to a surface |
US7195908B2 (en) * | 2002-10-31 | 2007-03-27 | Corning Incorporated | Supports treated with triamine for immobilizing biomolecules |
US7560160B2 (en) * | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040101822A1 (en) * | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
ES2208121B1 (en) * | 2002-11-29 | 2005-08-16 | Consejo Sup. Investig. Cientificas | ANTIBODIES AND IMMOBILIZED ANTIGENS ON SILICON MAGNETIC PARTICLES AS BIOSENSORS. |
CA2549994A1 (en) * | 2002-12-18 | 2004-08-12 | Hough Ear Institute | Otologic nanotechnology |
US7666410B2 (en) * | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
US6888862B2 (en) * | 2002-12-20 | 2005-05-03 | Eastman Kodak Company | Dye-doped polymer nanoparticle gain medium |
US20040120373A1 (en) * | 2002-12-20 | 2004-06-24 | Eastman Kodak Company | Dye-doped polymer nanoparticle gain medium for use in a laser |
JP3993089B2 (en) * | 2002-12-26 | 2007-10-17 | 良幸 川添 | Multiple particles and method for producing the same |
US7078276B1 (en) | 2003-01-08 | 2006-07-18 | Kovio, Inc. | Nanoparticles and method for making the same |
US7147921B2 (en) * | 2003-04-04 | 2006-12-12 | Ppg Industries Ohio, Inc. | Anti-fouling coatings containing silica-coated copper |
US20040254419A1 (en) * | 2003-04-08 | 2004-12-16 | Xingwu Wang | Therapeutic assembly |
JP5107573B2 (en) | 2003-04-25 | 2012-12-26 | ザ ペン ステイト リサーチ ファウンデーション | Systemic delivery methods and systems for growth-inhibiting lipid-derived bioactive compounds |
US8859000B2 (en) * | 2003-05-05 | 2014-10-14 | The Research Foundation Of State University Of New York | Synthesis of nanoparticles by an emulsion-gas contacting process |
EP1634050A4 (en) * | 2003-05-16 | 2008-06-18 | Univ Rochester | Colorimetric and fluorescent methods for sensing of oligonucleotides |
US20060166249A1 (en) * | 2003-05-16 | 2006-07-27 | University Of Rochester | Methods for separating short single-stranded nucleic acid from long single-and double-stranded nucleic acid, and associated biomolecular assays |
US20060239907A1 (en) * | 2003-06-03 | 2006-10-26 | The Trustees Of The University Of Pennsylvania | Stealthy nano agents |
US8651113B2 (en) * | 2003-06-18 | 2014-02-18 | Swr&D Inc. | Magnetically responsive nanoparticle therapeutic constructs and methods of making and using |
US7723311B2 (en) * | 2003-06-18 | 2010-05-25 | Nanobiomagnetics, Inc. | Delivery of bioactive substances to target cells |
US7344491B1 (en) * | 2003-11-26 | 2008-03-18 | Nanobiomagnetics, Inc. | Method and apparatus for improving hearing |
IL157437A0 (en) * | 2003-07-14 | 2004-03-28 | Superseal Ltd Superseal Ltd | Hydrophobic aggregate and applications thereof |
US20070042507A1 (en) * | 2003-07-16 | 2007-02-22 | Tsang Shik C | Composite nanoparticles |
CN1312479C (en) | 2003-08-08 | 2007-04-25 | 清华大学 | Nano fluorescent magnetic particle and its preparing method |
US20050112155A1 (en) * | 2003-08-11 | 2005-05-26 | Franck Giroud | Cosmetic composition comprising a passivated and optionally coated metal particles |
WO2005023961A1 (en) * | 2003-09-08 | 2005-03-17 | Waseda University | Novel fine fluorescent particle |
WO2005034205A2 (en) * | 2003-10-06 | 2005-04-14 | Dow Corning Corporation | Self assembling nanoparticle-polymer hybrids |
US8092595B1 (en) * | 2003-10-10 | 2012-01-10 | Sandia Corporation | Self-assembly of water-soluble nanocrystals |
US7837663B2 (en) | 2003-10-16 | 2010-11-23 | Kimberly-Clark Worldwide, Inc. | Odor controlling article including a visual indicating device for monitoring odor absorption |
US7488520B2 (en) * | 2003-10-16 | 2009-02-10 | Kimberly-Clark Worldwide, Inc. | High surface area material blends for odor reduction, articles utilizing such blends and methods of using same |
US7754197B2 (en) | 2003-10-16 | 2010-07-13 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using coordinated polydentate compounds |
US7438875B2 (en) | 2003-10-16 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified silica particles |
US7413550B2 (en) * | 2003-10-16 | 2008-08-19 | Kimberly-Clark Worldwide, Inc. | Visual indicating device for bad breath |
US7879350B2 (en) * | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7794737B2 (en) * | 2003-10-16 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Odor absorbing extrudates |
TWI240094B (en) * | 2003-12-11 | 2005-09-21 | Univ Nat Cheng Kung | Gradient refractive-index plastic rod and method for making the same |
GB0329310D0 (en) * | 2003-12-18 | 2004-01-21 | Univ Keele | Method |
US20050282182A1 (en) * | 2003-12-30 | 2005-12-22 | Universal Bio Research Co., Ltd. | Reaction vessel and reaction apparatus comprising three-dimensional particle array |
US7323696B2 (en) * | 2004-01-09 | 2008-01-29 | Applera Corporation | Phosphor particle coded beads |
US9028829B2 (en) * | 2004-02-20 | 2015-05-12 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
US8562505B2 (en) | 2004-02-20 | 2013-10-22 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
US7846201B2 (en) * | 2004-02-20 | 2010-12-07 | The Children's Hospital Of Philadelphia | Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex |
US7190264B2 (en) * | 2004-03-05 | 2007-03-13 | Simon Fraser University | Wireless computer monitoring device with automatic arming and disarming |
JP2005265654A (en) * | 2004-03-19 | 2005-09-29 | Hitachi Maxell Ltd | Compounded particles |
US7745001B2 (en) * | 2004-03-23 | 2010-06-29 | University Of New Orleans Research And Technology Foundation, Inc. | Synthesis of nanoassemblies containing luminescent quantum dots and magnetic nanoparticles |
EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
US20050220714A1 (en) * | 2004-04-01 | 2005-10-06 | Susan Kauzlarich | Agents for use in magnetic resonance and optical imaging |
US20060018835A1 (en) * | 2004-04-02 | 2006-01-26 | General Electric Company | Nanoparticles with inorganic core and methods of using them |
EP1756178B1 (en) * | 2004-04-02 | 2012-02-29 | Nexttec GmbH | Process for manufacturing a composite sorbent material for chromatographical separation of biopolymers |
US20070281567A1 (en) * | 2004-04-05 | 2007-12-06 | Solid Water Holding | Waterproof/breathable technical apparel |
US20070141940A1 (en) * | 2005-10-28 | 2007-06-21 | Lightweight, breathable, waterproof, soft shell composite apparel and technical alpine apparel | |
US20070294920A1 (en) * | 2005-10-28 | 2007-12-27 | Soft shell boots and waterproof /breathable moisture transfer composites and liner for in-line skates, ice-skates, hockey skates, snowboard boots, alpine boots, hiking boots and the like | |
CN1232608C (en) * | 2004-04-06 | 2005-12-21 | 中国科学院长春应用化学研究所 | Method for synthesizing nano semiconductor luminescence material on interface bewteen liquid-liquid |
US20050226911A1 (en) * | 2004-04-13 | 2005-10-13 | Bringley Joseph F | Article for inhibiting microbial growth in physiological fluids |
US7357863B2 (en) * | 2004-04-13 | 2008-04-15 | Eastman Kodak Company | Container for inhibiting microbial growth in liquid nutrients |
US7258786B2 (en) * | 2004-04-13 | 2007-08-21 | Eastman Kodak Company | Container for inhibiting microbial growth in liquid nutrients |
US7361275B2 (en) * | 2004-04-13 | 2008-04-22 | Eastman Kodak Company | Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks |
US7384545B2 (en) * | 2004-04-13 | 2008-06-10 | Eastman Kodak Company | Container for inhibiting microbial growth in liquid nutrients |
WO2005102396A2 (en) | 2004-04-20 | 2005-11-03 | Emory University | Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof |
US7462452B2 (en) | 2004-04-30 | 2008-12-09 | Pacific Biosciences Of California, Inc. | Field-switch sequencing |
US7407816B2 (en) | 2004-05-07 | 2008-08-05 | Gentius, Inc | Isoelectric particles and uses thereof |
EP1773936B1 (en) * | 2004-06-01 | 2015-09-02 | The Penn State Research Foundation | Unagglomerated core/shell nanocomposite particles |
US20080042106A1 (en) * | 2004-06-04 | 2008-02-21 | Basf Aktiengesellschaft | Method for Marking Materials |
CN101057145B (en) | 2004-06-23 | 2014-10-22 | 得克萨斯系统大学评议会 | Methods and compositions for the detection of biological molecules using a two particle complex |
FI120318B (en) * | 2004-06-23 | 2009-09-15 | M Real Oyj | Silicon containing starch composites, process for making them and use in making paper and paperboard |
US20050287680A1 (en) * | 2004-06-25 | 2005-12-29 | Srivatsa Venkatasubbarao | Multianalyte assay method |
US7405002B2 (en) | 2004-08-04 | 2008-07-29 | Agency For Science, Technology And Research | Coated water-soluble nanoparticles comprising semiconductor core and silica coating |
KR100604976B1 (en) | 2004-09-03 | 2006-07-28 | 학교법인연세대학교 | Water-Soluble Nanoparticles Stabilized with Multi-Functional Group Ligands |
US7534489B2 (en) | 2004-09-24 | 2009-05-19 | Agency For Science, Technology And Research | Coated composites of magnetic material and quantum dots |
WO2006037837A1 (en) * | 2004-10-01 | 2006-04-13 | Turun Yliopisto | Dye particle and its preparation and use |
FR2877571B1 (en) * | 2004-11-05 | 2007-04-13 | Nanobiotix Sarl | NANOPARTICLES WITH INTRACELLULAR TARGETING ELEMENT, PREPARATION AND USES |
US7947772B2 (en) * | 2004-11-10 | 2011-05-24 | The Regents Of The University Of Michigan | Multiphasic nano-components comprising colorants |
WO2006137936A2 (en) * | 2004-11-10 | 2006-12-28 | The Regents Of The University Of Michigan | Multi-phasic nanoparticles |
US8043480B2 (en) * | 2004-11-10 | 2011-10-25 | The Regents Of The University Of Michigan | Methods for forming biodegradable nanocomponents with controlled shapes and sizes via electrified jetting |
US8187708B2 (en) * | 2004-11-10 | 2012-05-29 | The Regents Of The University Of Michigan | Microphasic micro-components and methods for controlling morphology via electrified jetting |
US20090098044A1 (en) * | 2004-11-15 | 2009-04-16 | Australian Nuclear Science And Technology Organisation | Solid particles from controlled destabilisation of microemulsions |
WO2006050579A1 (en) | 2004-11-15 | 2006-05-18 | Australian Nuclear Science & Technology Organisation | Solid particles from controlled destabilisation of microemulsions |
JP4916654B2 (en) * | 2004-11-16 | 2012-04-18 | 国立大学法人東北大学 | Method for producing nanocomposite structure |
US7306963B2 (en) * | 2004-11-30 | 2007-12-11 | Spire Corporation | Precision synthesis of quantum dot nanostructures for fluorescent and optoelectronic devices |
US7524776B2 (en) * | 2004-11-30 | 2009-04-28 | Spire Corporation | Surface-activation of semiconductor nanostructures for biological applications |
US7514725B2 (en) * | 2004-11-30 | 2009-04-07 | Spire Corporation | Nanophotovoltaic devices |
US20060147943A1 (en) * | 2004-12-30 | 2006-07-06 | Lewis Mark A | Substrates having pendant epoxide groups for binding biomolecules and methods of making and using thereof |
US20080135490A1 (en) * | 2005-01-07 | 2008-06-12 | Board Of Trustees Of The University Of Arkansas | Quantum dot biolabeling and immunomagnetic separation for detection of contaminants |
US20060217893A1 (en) * | 2005-01-07 | 2006-09-28 | Yanbin Li | Method for detecting an unknown contaminant concentration in a substance |
US7699979B2 (en) * | 2005-01-07 | 2010-04-20 | Board Of Trustees Of The University Of Arkansas | Separation system and efficient capture of contaminants using magnetic nanoparticles |
US8062729B2 (en) | 2005-01-14 | 2011-11-22 | Ndsu Research Foundation | Polymeric material with surface microdomains |
US20060293396A1 (en) * | 2005-01-14 | 2006-12-28 | Eastman Kodak Company | Amine polymer-modified nanoparticulate carriers |
US7718262B2 (en) | 2005-01-20 | 2010-05-18 | Luminex Corporation | Magnetic microspheres for use in fluorescence-based applications |
US8084275B2 (en) * | 2005-02-08 | 2011-12-27 | Fujifilm Corporation | Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface |
BRPI0607321A2 (en) * | 2005-02-14 | 2009-09-01 | Australian Nuclear Science Tech Org | layered nanoparticles |
EP1861710A4 (en) * | 2005-03-03 | 2008-07-23 | Univ North Dakota | Surfaces coated with target-induced fluorescent compounds for detection of target elements |
US7781228B2 (en) * | 2005-04-07 | 2010-08-24 | Menon & Associates, Inc. | Magnetic resonance system and method to detect and confirm analytes |
US8084001B2 (en) * | 2005-05-02 | 2011-12-27 | Cornell Research Foundation, Inc. | Photoluminescent silica-based sensors and methods of use |
WO2006121920A2 (en) * | 2005-05-05 | 2006-11-16 | Beth Israel Deaconess Medical Center, Inc. | Micro-scale resonant devices and methods of use |
US7771833B2 (en) * | 2005-05-09 | 2010-08-10 | Ndsu Research Foundation | Anti-fouling materials containing cationic polysiloxanes |
EP1721603A1 (en) * | 2005-05-11 | 2006-11-15 | Albert-Ludwigs-Universität Freiburg | Nanoparticles for bioconjugation |
EP1726609A1 (en) * | 2005-05-25 | 2006-11-29 | DSM IP Assets B.V. | Hydrophobic coating |
WO2006133519A1 (en) | 2005-06-17 | 2006-12-21 | Australian Nuclear Science And Technology Organisation | Particles comprising a releasable dopant therein |
WO2006136314A1 (en) | 2005-06-23 | 2006-12-28 | Siemens Medical Solutions Diagnostics Gmbh | Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use |
JP2007040978A (en) * | 2005-06-30 | 2007-02-15 | Fujifilm Corp | Method for separating objective element using magnetic nanoparticles |
IL169678A (en) | 2005-07-14 | 2010-11-30 | Innova Sa | Sweetener compositions |
KR100731913B1 (en) | 2005-09-20 | 2007-06-25 | 한양대학교 산학협력단 | Method for manufacturing nanohybrid particle using for biomolecule detection, biomolecule detection system, biomolecule detection method, and analysis apparatus using for biomolecule detection using nanohybrid particle |
WO2007035871A1 (en) * | 2005-09-21 | 2007-03-29 | Massachusetts Institute Of Technology | Systems and methods for tuning properties of nanoparticles |
CN101321686A (en) * | 2005-10-07 | 2008-12-10 | 佛罗里达大学研究基金会有限公司 | Multiple component nanoparticles for multiplexed signaling and optical encoding |
KR100771773B1 (en) * | 2005-11-01 | 2007-10-30 | 삼성전기주식회사 | A Composite Nickel Particle and A Preparing Method Thereof |
KR100745744B1 (en) * | 2005-11-11 | 2007-08-02 | 삼성전기주식회사 | A coating method of nano particle |
US20090226724A1 (en) * | 2005-11-28 | 2009-09-10 | National Research Council Of Canada | Multifunctional nanostructure and method |
EP1957398B1 (en) * | 2005-12-06 | 2012-01-18 | LG Chem, Ltd. | Method for preparing core-shell type nanoparticles |
US7592042B1 (en) | 2005-12-19 | 2009-09-22 | Fujifilm Corporation | Reverse micelle method of producing core/shell particles |
US9913917B2 (en) | 2005-12-22 | 2018-03-13 | Visen Medical, Inc. | Biocompatible fluorescent metal oxide nanoparticles |
US20080267557A1 (en) * | 2005-12-29 | 2008-10-30 | Zheng Wang | Integrated Magneto-Optical Devices for Uni-Directional Optical Resonator Systems |
US10100266B2 (en) | 2006-01-12 | 2018-10-16 | The Board Of Trustees Of The University Of Arkansas | Dielectric nanolubricant compositions |
CA2636932C (en) | 2006-01-12 | 2014-03-25 | The Board Of Trustees Of The University Of Arkansas | Nanoparticle compositions and methods for making and using the same |
US20070166730A1 (en) | 2006-01-19 | 2007-07-19 | Menon & Associates, Inc. | Magnetic resonance system and method to detect and confirm analytes |
CA2571904A1 (en) * | 2006-02-15 | 2007-08-15 | Fio Corporation | System and method of detecting pathogens |
DE102006007564A1 (en) * | 2006-02-16 | 2007-08-30 | Röhm Gmbh | Nanoscale superparamagnetic poly (meth) acrylate polymers |
JP4711306B2 (en) * | 2006-02-20 | 2011-06-29 | 双葉電子工業株式会社 | Nanocarbon particle dispersion, method for producing the same, and method for producing core-shell type nanocarbon particles |
KR100745745B1 (en) * | 2006-02-21 | 2007-08-02 | 삼성전기주식회사 | Nano-composite material and the maunfacturing method for the same |
KR100713745B1 (en) * | 2006-02-27 | 2007-05-07 | 연세대학교 산학협력단 | Water-soluble magnetic or metal oxide nanoparticles coated with ligands and preparation method thereof |
JP2007269770A (en) * | 2006-03-09 | 2007-10-18 | Mitsubishi Chemicals Corp | Functional magnetic super-nanoparticle and use thereof |
WO2007112356A2 (en) * | 2006-03-24 | 2007-10-04 | University Of Florida Research Foundation, Inc. | Core-shell nanocapsules and applications thereof |
WO2007110917A1 (en) * | 2006-03-27 | 2007-10-04 | Tokyo Institute Of Technology | Process for producing polymer-coated ferromagnetic particle, and polymer-coated ferromagnetic particle |
JP4568862B2 (en) * | 2006-04-14 | 2010-10-27 | 独立行政法人産業技術総合研究所 | Core-shell type particle and method for producing the same |
WO2007123846A2 (en) * | 2006-04-17 | 2007-11-01 | Rensselaer Polytechnic Institute | Synthesis, functionalization and assembly of monodisperse high-coercivity silica-capped fept nanomagnets of tunable size, composition and thermal stability from microemulsions |
US7977103B2 (en) | 2006-04-20 | 2011-07-12 | Kimberly-Clark Worldwide, Inc. | Method for detecting the onset of ovulation |
WO2007124131A2 (en) * | 2006-04-20 | 2007-11-01 | The University Of North Carolina At Chapel Hill | Hybrid nanomaterials as multimodal imaging contrast agents |
WO2007146680A1 (en) * | 2006-06-06 | 2007-12-21 | Florida State University Research Foundation , Inc. | Stabilized silica colloid |
WO2007149310A2 (en) * | 2006-06-16 | 2007-12-27 | The Regents Of The University Of Michigan | Multiphasic biofunctional nano-components and methods for use thereof |
DE102006030690A1 (en) * | 2006-07-04 | 2008-01-10 | Grimm, Friedrich, Dipl.-Ing. | Synthetically producing silicic acid, useful e.g. as cosmetic product, drying agent, food additive and as insulating material, comprises doping silicic acid with a metal ion to give micro- and nano-scalic highly dispersed pigment |
US20080058473A1 (en) * | 2006-08-31 | 2008-03-06 | Yakov Freidzon | Latex for low VOC paint having improved block resistance, open time and water-softening resistance |
US20100120016A1 (en) * | 2006-09-01 | 2010-05-13 | Yanbin Li | Methods and systems for detection of contaminants |
US20080118687A1 (en) * | 2006-11-20 | 2008-05-22 | Alex Andrew Burns | Memory impregnated thermoplastic article |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
US8317002B2 (en) * | 2006-12-08 | 2012-11-27 | The Regents Of The University Of California | System of smart colloidal dampers with controllable damping curves using magnetic field and method of using the same |
CA2580589C (en) * | 2006-12-19 | 2016-08-09 | Fio Corporation | Microfluidic detection system |
FI20070174A0 (en) * | 2007-02-28 | 2007-02-28 | Delsitech Oy | A process for the preparation of silica compositions, silica compositions and their uses |
WO2008114532A1 (en) * | 2007-03-16 | 2008-09-25 | Konica Minolta Medical & Graphic, Inc. | Process for producing core/shell semiconductor nanoparticle and semiconductor nanoparticle aggregate produced thereby |
US20100092384A1 (en) * | 2007-03-19 | 2010-04-15 | The Junited States Of America As Represented By Secretary, Dept. Of Health And Human Service | Multifunctional nanoparticles and compositions and methods of use thereof |
WO2008119184A1 (en) | 2007-04-02 | 2008-10-09 | Fio Corporation | System and method of deconvolving multiplexed fluorescence spectral signals generated by quantum dot optical coding technology |
US20080255403A1 (en) * | 2007-04-13 | 2008-10-16 | Ethicon Endo-Surgery, Inc. | Magnetic nanoparticle therapies |
WO2008125940A2 (en) * | 2007-04-17 | 2008-10-23 | Pfizer Products Inc. | Nanoparticles comprising non-crystalline drug |
US20080269086A1 (en) * | 2007-04-30 | 2008-10-30 | Atanu Adhvaryu | Functionalized nanosphere lubricants |
WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
US7811830B2 (en) * | 2007-05-18 | 2010-10-12 | New Mexico Technical Research Foundation | Photosensitizers for photodynamic therapy at infrared excitation |
EP2162120B1 (en) * | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US8287810B2 (en) | 2007-06-20 | 2012-10-16 | Board Of Trustees Of Michigan State University | Electrically-active ferromagnetic particle conductimetric biosensor test kit |
WO2009000084A1 (en) | 2007-06-22 | 2008-12-31 | Fio Corporation | Systems and methods for manufacturing quantum dot-doped polymer microbeads |
CA2693055C (en) * | 2007-07-09 | 2012-02-21 | Fio Corporation | Systems and methods for enhancing fluorescent detection of target molecules in a test sample |
US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
US9023372B2 (en) * | 2007-07-18 | 2015-05-05 | University Of Maryland | Metal-enhanced fluorescence nanoparticles |
SG183034A1 (en) * | 2007-07-23 | 2012-08-30 | Fio Corp | A method and system for collating, storing, analyzing and enabling access to collected and analyzed data associated with biological and environmental test subjects |
US20090047222A1 (en) * | 2007-08-15 | 2009-02-19 | Ben Gu | Color Stable Peroxide Containing Dentifrice Formulations With Dye Encapsulated Silica Shell Nanoparticles |
US9174186B2 (en) * | 2007-08-17 | 2015-11-03 | University Of Florida Research Foundation, Inc. | Supercrystalline colloidal particles and method of production |
US20110028662A1 (en) * | 2007-08-31 | 2011-02-03 | Hybrid Silica Technologies, Inc. | Peg-coated core-shell silica nanoparticles and methods of manufacture and use |
US8709394B2 (en) * | 2007-09-28 | 2014-04-29 | Ndsu Research Foundation | Antimicrobial polysiloxane materials containing metal species |
CN101861203B (en) * | 2007-10-12 | 2014-01-22 | Fio公司 | Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto |
AU2008325088A1 (en) | 2007-11-06 | 2009-05-14 | T2 Biosystems, Inc. | Small magnet and RF coil for magnetic resonance relaxometry |
KR101077966B1 (en) * | 2007-11-30 | 2011-10-31 | 고려대학교 산학협력단 | A nanoparticle for separating peptide, method for preparing the same, and method for separating peptide using the same |
WO2009069959A2 (en) * | 2007-11-30 | 2009-06-04 | Korea University Industrial & Academic Collaboration Foundation | A nanoparticle for separating peptide, method for preparing the same, and method for separating peptide using the same |
EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
EP2240162A4 (en) * | 2007-12-06 | 2013-10-09 | Bend Res Inc | Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer |
US8268436B2 (en) * | 2007-12-15 | 2012-09-18 | The Goodyear Tire & Rubber Company | Tire with indicia containing composite magnetic nanoparticles |
IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
US8357426B2 (en) * | 2008-01-11 | 2013-01-22 | Nanomateriales S.A. De C.V. | Single step milling and surface coating process for preparing stable nanodispersions |
KR101475520B1 (en) * | 2008-01-14 | 2014-12-23 | 삼성전자주식회사 | Quantum dot ink composition for inkjet printing and electronic device using the same |
WO2009102429A2 (en) * | 2008-02-11 | 2009-08-20 | University Of North Dakota | Method for producing nanoparticles of a selected size |
US7785998B2 (en) * | 2008-02-21 | 2010-08-31 | Micron Technology, Inc. | Methods of forming dispersions of nanoparticles, and methods of forming flash memory cells |
US20110135571A1 (en) * | 2008-02-22 | 2011-06-09 | Wenbin Lin | Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents |
US9011913B2 (en) * | 2008-04-04 | 2015-04-21 | The Regents Of The University Of California | Use of functionalized magnetic nanoparticles in cancer detection and treatment |
EP2265174B1 (en) * | 2008-04-04 | 2018-06-06 | The Regents of The University of California | Functionalized magnetic nanoparticles and methods of use thereof |
WO2009143720A1 (en) * | 2008-05-27 | 2009-12-03 | The Chinese University Of Hong Kong | Nanoparticles, methods of making same and cell labelling using same |
US20150147378A1 (en) * | 2008-05-30 | 2015-05-28 | Rutgers, The State University Of New Jersy | Copolymer-xerogel nanocomposites useful for drug delivery |
KR101421619B1 (en) * | 2008-05-30 | 2014-07-22 | 삼성전자 주식회사 | Nanocrystal-metal oxide-polymer composite and preparation method thereof |
US20120066926A1 (en) * | 2008-06-09 | 2012-03-22 | Kuniyil Prabhakaran | Non-toxic multifunctional nanoparticles using sonication-aided incorporation of dopants |
JP5279357B2 (en) * | 2008-06-12 | 2013-09-04 | キヤノン株式会社 | Composite particle, method for producing the same, dispersion, magnetic biosensing device, and magnetic biosensing method |
WO2009155704A1 (en) | 2008-06-25 | 2009-12-30 | Fio Corporation | Bio-threat alert system |
US8465855B2 (en) * | 2008-07-16 | 2013-06-18 | International Business Machines Corporation | Protective coating of magnetic nanoparticles |
WO2010007803A1 (en) * | 2008-07-17 | 2010-01-21 | コニカミノルタエムジー株式会社 | Nanoparticle labeling and system using the nanoparticle labeling |
AP2011005589A0 (en) * | 2008-07-24 | 2011-02-28 | Tata Chemicals Ltd | A process for forming a rice husk ash composition. |
AP2011005588A0 (en) * | 2008-07-24 | 2011-02-28 | Tata Chemicals Ltd | A process for forming a rice husk ash composition. |
US8216961B2 (en) * | 2008-08-27 | 2012-07-10 | Korea University Research And Business Foundation | Nanoparticles including metal oxide having catalytic activity |
US20100054988A1 (en) * | 2008-08-29 | 2010-03-04 | Kwangyeol Lee | Photocatalytic nanocapsule and fiber for water treatment |
CN105759021A (en) | 2008-08-29 | 2016-07-13 | Fio公司 | Single-use Handheld Diagnostic Test Device And Associated System And Method For Testing Biological And Environmental Test Samples |
US7897164B2 (en) * | 2008-10-30 | 2011-03-01 | Warsaw Orthopedic, Inc | Compositions and methods for nucleus pulposus regeneration |
US8221791B1 (en) | 2008-12-10 | 2012-07-17 | University Of Central Florida Research Foundation, Inc. | Silica-based antibacterial and antifungal nanoformulation |
US10080578B2 (en) | 2008-12-16 | 2018-09-25 | Nico Corporation | Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications |
WO2010081219A1 (en) | 2009-01-13 | 2010-07-22 | Fio Corporation | A handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test |
US20110171749A1 (en) * | 2009-03-02 | 2011-07-14 | Board Of Trustees Of Michigan State University | Nanoparticle tracer-based electrochemical dna sensor for detection of pathogens-amplification by a universal nano-tracer (aunt) |
US8827971B2 (en) | 2011-04-29 | 2014-09-09 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
WO2010101620A2 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
US8053744B2 (en) * | 2009-04-13 | 2011-11-08 | Src, Inc. | Location analysis using nucleic acid-labeled tags |
WO2010121064A2 (en) * | 2009-04-15 | 2010-10-21 | Cornell Research Foundation, Inc. | Improved fluorescent silica nanoparticles through silica densification |
EP2430112B1 (en) | 2009-04-23 | 2018-09-12 | The University of Chicago | Materials and methods for the preparation of nanocomposites |
US20100278734A1 (en) * | 2009-04-29 | 2010-11-04 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
US20100278748A1 (en) * | 2009-04-29 | 2010-11-04 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
US20100278749A1 (en) * | 2009-04-29 | 2010-11-04 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
US20100330366A1 (en) * | 2009-06-30 | 2010-12-30 | Keiser Bruce A | Silica-based particle composition |
EP2451442A4 (en) | 2009-07-09 | 2014-02-12 | Oshadi Drug Administration Ltd | Matrix carrier compositions, methods and uses |
US8579052B2 (en) * | 2009-08-07 | 2013-11-12 | Baker Hughes Incorporated | Polycrystalline compacts including in-situ nucleated grains, earth-boring tools including such compacts, and methods of forming such compacts and tools |
US8800693B2 (en) | 2010-11-08 | 2014-08-12 | Baker Hughes Incorporated | Polycrystalline compacts including nanoparticulate inclusions, cutting elements and earth-boring tools including such compacts, and methods of forming same |
US8496076B2 (en) * | 2009-10-15 | 2013-07-30 | Baker Hughes Incorporated | Polycrystalline compacts including nanoparticulate inclusions, cutting elements and earth-boring tools including such compacts, and methods of forming such compacts |
US8727042B2 (en) * | 2009-09-11 | 2014-05-20 | Baker Hughes Incorporated | Polycrystalline compacts having material disposed in interstitial spaces therein, and cutting elements including such compacts |
KR101123394B1 (en) | 2009-09-24 | 2012-03-23 | 한국세라믹기술원 | Manufacturing method of red ceramic pigment having thermal stability |
US9540822B2 (en) | 2009-11-24 | 2017-01-10 | Certainteed Corporation | Composite nanoparticles for roofing granules, roofing shingles containing such granules, and process for producing same |
FR2954796B1 (en) * | 2009-12-24 | 2016-07-01 | Total Sa | USE OF NANOPARTICLES FOR THE MARKING OF PETROLEUM FIELD INJECTION WATER |
EP2518127B1 (en) * | 2009-12-25 | 2018-07-18 | Konica Minolta Medical & Graphic, Inc. | Biosubstance labelling agent |
EP2524219A4 (en) * | 2010-01-14 | 2013-08-07 | Univ Central Florida Res Found | Methods for biomolecule and biomolecule complex (bmc) detection and analysis and the use of such for research and medical diagnosis |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
EP2540282A2 (en) * | 2010-02-23 | 2013-01-02 | SNU R & DB Foundation | Surface-modified tantalum oxide nanoparticles, preparation method thereof, and contrast medium for x-ray computed tomography and highly dielectric thin film using same |
US20130108552A1 (en) * | 2010-03-01 | 2013-05-02 | University Of Florida Research Foundation Inc. | Near-ir indocyanine green doped multimodal silica nanoparticles and methods for making the same |
EP2542759A4 (en) * | 2010-03-04 | 2015-11-18 | Peter E Rose | Colloidal-crystal quantum dots as tracers in underground formations |
MX2012011104A (en) | 2010-03-30 | 2012-11-29 | Univ Central Florida Res Found | Multifunctional silica-based compositions and gels, methods of making them, and methods of using them. |
US8557329B2 (en) | 2010-05-06 | 2013-10-15 | International Business Machines Corporation | Method for silica encapsulation of magnetic particles |
WO2011156895A2 (en) * | 2010-06-14 | 2011-12-22 | National Research Council Of Canada | Magnetic nanoparticles and uses thereof |
US8703493B2 (en) | 2010-06-15 | 2014-04-22 | Src, Inc. | Location analysis using fire retardant-protected nucleic acid-labeled tags |
US9555136B2 (en) | 2010-06-21 | 2017-01-31 | University Of Washington Through Its Center For Commercialization | Coated magnetic nanoparticles |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
DE102010030822A1 (en) * | 2010-07-01 | 2012-01-05 | Evonik Degussa Gmbh | Partially silylated magnetic particles and dispersions thereof |
JP2013538069A (en) | 2010-07-16 | 2013-10-10 | セブンス センス バイオシステムズ,インコーポレーテッド | Low pressure environment for fluid transfer devices |
US8518288B2 (en) | 2010-07-27 | 2013-08-27 | Toyota Motor Engineering & Manufacturing North America, Inc. | Synthesis of nanocomposite thermoelectric material |
US8716027B2 (en) | 2010-08-03 | 2014-05-06 | Src, Inc. | Nucleic acid-labeled tags associated with odorant |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
DE102011010756A1 (en) | 2010-09-14 | 2012-03-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Photostimulable particle systems, processes for their preparation and uses |
IL208594A (en) | 2010-10-10 | 2014-11-30 | Innova Sa | Sweetener compositions comprising a solid eutectic melt mixture combination of cellulose and a sweetener carbohydrate and methods of producing same |
WO2012049251A1 (en) * | 2010-10-13 | 2012-04-19 | Pharmadiagnostics Nv | Method for coating nanoparticles |
WO2012054841A2 (en) | 2010-10-22 | 2012-04-26 | The Regents Of The University Of Michigan | Optical devices with switchable particles |
CN101966344B (en) * | 2010-10-29 | 2012-04-11 | 中国科学院上海硅酸盐研究所 | Hollow core-shell nanometer mesoporous medicament carrying system with magnetism and luminescent performance, preparation method and application thereof |
WO2012158196A2 (en) | 2010-11-05 | 2012-11-22 | Massachusetts Institute Of Technology | Core-shell magnetic particles and related methods |
US8808202B2 (en) | 2010-11-09 | 2014-08-19 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
EP2641245A4 (en) * | 2010-11-15 | 2016-02-17 | Trustees Of The University Of Alabama For And On Behalf Of The University Of Alabama Board Of | Magnetic exchange coupled core-shell nanomagnets |
TWI403358B (en) * | 2010-12-29 | 2013-08-01 | Univ Nat Taiwan | Method for dispersing metallic nanoparticle and composite thereof |
US8802234B2 (en) * | 2011-01-03 | 2014-08-12 | Imra America, Inc. | Composite nanoparticles and methods for making the same |
US8679858B2 (en) * | 2011-01-11 | 2014-03-25 | The Board Of Trustees Of The Leland Stanford Junior University | Lanthanide mass dots: nanoparticle isotope tags |
JP5375855B2 (en) | 2011-02-22 | 2013-12-25 | トヨタ自動車株式会社 | Decorative coating |
RU2636460C2 (en) * | 2011-02-23 | 2017-11-23 | Ив Байомедикал, Инк. | Systems and methods for application of transcription sequencing dependent on rotation |
CN106729771A (en) | 2011-04-21 | 2017-05-31 | 加利福尼亚大学董事会 | Functionalized magnetic nanoparticles and the purposes in amyloid deposition and neurofibrillary tangles imaging |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
CA2833175A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Devices and methods for collection and/or manipulation of blood spots or other bodily fluids |
WO2012173933A2 (en) | 2011-06-11 | 2012-12-20 | University Of Central Florida Research Foundation, Inc. | Activatable nanoprobes for intracellular drug delivery |
US9849512B2 (en) | 2011-07-01 | 2017-12-26 | Attostat, Inc. | Method and apparatus for production of uniformly sized nanoparticles |
EP3494974B1 (en) | 2011-07-08 | 2023-10-18 | The University of North Carolina at Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
JP5844902B2 (en) | 2011-08-10 | 2016-01-20 | マグフォース アーゲー | Aggregation of magnetic nanoparticles coated with alkoxysilanes |
WO2013030240A1 (en) * | 2011-08-29 | 2013-03-07 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Phase transfer reactions |
US9491946B2 (en) | 2011-11-01 | 2016-11-15 | University Of Central Florida Research Foundation, Inc. | Ag loaded silica nanoparticle/nanogel formulation, methods of making, and methods of use |
EP2776152B1 (en) | 2011-11-09 | 2018-03-28 | The Regents of The University of California | Superparamagnetic colloids with enhanced charge stability for high quality magnetically tunable photonic structures |
CN102406950A (en) * | 2011-11-29 | 2012-04-11 | 中国科学院上海硅酸盐研究所 | Manganese-based magnetic resonance imaging (MRI) contrast agent and preparation method and application thereof |
US20130243699A1 (en) * | 2011-12-07 | 2013-09-19 | Regents Of The University Of Minnesota | Biodegradable Magnetic Nanoparticles and Related Methods |
TWI525184B (en) | 2011-12-16 | 2016-03-11 | 拜歐菲樂Ip有限責任公司 | Cryogenic injection compositions, systems and methods for cryogenically modulating flow in a conduit |
KR20130084091A (en) | 2012-01-16 | 2013-07-24 | 삼성전자주식회사 | Image forming apparatus |
CN102580635B (en) * | 2012-01-19 | 2013-10-16 | 黑龙江大学 | Method for preparing double-property polymer microspheres |
WO2013131057A1 (en) | 2012-03-01 | 2013-09-06 | Quidel Corporation | System and apparatus for point-of-care diagnostics |
US11061020B2 (en) | 2012-03-01 | 2021-07-13 | Quidel Corporation | Interactive test device and apparatus with timing mechanism |
JP5986308B2 (en) | 2012-06-22 | 2016-09-06 | アップル インコーポレイテッド | White-like anodic oxide film and method for forming the same |
US8486870B1 (en) | 2012-07-02 | 2013-07-16 | Ajay P. Malshe | Textured surfaces to enhance nano-lubrication |
US8476206B1 (en) | 2012-07-02 | 2013-07-02 | Ajay P. Malshe | Nanoparticle macro-compositions |
DE102012211947A1 (en) | 2012-07-09 | 2014-01-09 | Evonik Industries Ag | Magnetic core-shell particles with high separation efficiency |
JP2015530962A (en) * | 2012-07-18 | 2015-10-29 | ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシズ | Method for preparing silica-coated nanodiamond |
US9493876B2 (en) * | 2012-09-14 | 2016-11-15 | Apple Inc. | Changing colors of materials |
JP6085035B2 (en) * | 2012-11-16 | 2017-02-22 | エスエヌユー アールアンドディービー ファウンデーションSnu R&Db Foundation | Coded polymer particles |
CN103116026B (en) * | 2013-01-29 | 2015-04-15 | 南昌大学 | Quick detection method for food-borne pathogens based on immunomagnetic separation of Fe3O4 nano materials |
EP2956258A1 (en) | 2013-02-15 | 2015-12-23 | Regents of the University of Minnesota | Particle functionalization |
US9296771B2 (en) | 2013-03-15 | 2016-03-29 | The United States Of America, As Represented By The Secretary Of The Navy | Large scale preparation method for functionalizing the surface of magnetic microparticles with an inorganic phosphorous dendrimer |
JP5714660B2 (en) * | 2013-07-11 | 2015-05-07 | トヨタ自動車株式会社 | Method for producing nanocomposite thermoelectric conversion material |
US9409148B2 (en) | 2013-08-08 | 2016-08-09 | Uchicago Argonne, Llc | Compositions and methods for direct capture of organic materials from process streams |
US9781936B2 (en) | 2013-10-09 | 2017-10-10 | University Of Central Florida Research Foundation, Inc. | Compositions, methods of making a composition, and methods of use |
US9181629B2 (en) | 2013-10-30 | 2015-11-10 | Apple Inc. | Methods for producing white appearing metal oxide films by positioning reflective particles prior to or during anodizing processes |
US10517822B2 (en) | 2013-11-06 | 2019-12-31 | The University Of Chicago | Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers |
US9839974B2 (en) | 2013-11-13 | 2017-12-12 | Apple Inc. | Forming white metal oxide films by oxide structure modification or subsurface cracking |
WO2015085189A1 (en) | 2013-12-06 | 2015-06-11 | Quidel Corporation | Method for reducing analyzer variability using a normalization target |
US9215877B2 (en) | 2014-02-05 | 2015-12-22 | University Of Central Florida Research Foundation, Inc. | Compositions including a vacancy-engineered(VE)-ZnO nanocomposite, methods of making a composition , method of using a composition |
EP2905034A1 (en) * | 2014-02-06 | 2015-08-12 | Maillefer Instruments Holding S.À.R.L. | Irrigation solution with nanoparticles for endodontics |
US9302228B2 (en) | 2014-02-28 | 2016-04-05 | Pall Corporation | Charged porous polymeric membrane with high void volume |
US9764292B2 (en) | 2014-02-28 | 2017-09-19 | Pall Corporation | Porous polymeric membrane with high void volume |
US9776142B2 (en) | 2014-02-28 | 2017-10-03 | Pall Corporation | Porous polymeric membrane with high void volume |
US9309126B2 (en) | 2014-02-28 | 2016-04-12 | Pall Corporation | Rapidly dissolvable nanoparticles |
US9446355B2 (en) | 2014-02-28 | 2016-09-20 | Pall Corporation | Porous polymeric membrane with high void volume |
US9737860B2 (en) | 2014-02-28 | 2017-08-22 | Pall Corporation | Hollow fiber membrane having hexagonal voids |
US9610548B2 (en) | 2014-02-28 | 2017-04-04 | Pall Corporation | Composite porous polymeric membrane with high void volume |
US9561473B2 (en) | 2014-02-28 | 2017-02-07 | Pall Corporation | Charged hollow fiber membrane having hexagonal voids |
US10231476B2 (en) | 2014-04-04 | 2019-03-19 | Douxmatok Ltd | Sweetener compositions and foods, beverages, and consumable products made thereof |
US10207004B2 (en) | 2014-04-04 | 2019-02-19 | Douxmatok Ltd | Method for producing sweetener compositions and sweetener compositions |
US20160242439A1 (en) | 2014-04-04 | 2016-08-25 | Douxmatok Ltd | Method for producing sweetener compositions and sweetener compositions |
US9181838B2 (en) | 2014-04-07 | 2015-11-10 | Ford Global Technologies, Llc | Temperature maintenance and regulation of vehicle exhaust catalyst systems with phase change materials |
US9566552B2 (en) | 2014-04-07 | 2017-02-14 | Ford Global Technologies, Llc | Temperature maintenance and regulation of vehicle exhaust catalyst systems with phase change materials |
US20160010080A1 (en) * | 2014-07-09 | 2016-01-14 | Magqu Co., Ltd. | A method for preparing silica-coated magnetic bead |
GB201416354D0 (en) | 2014-09-16 | 2014-10-29 | Ecole Polytech | Monolayer nanocapsules |
US9919363B2 (en) | 2014-09-23 | 2018-03-20 | Attostat, Inc. | System and method for making non-spherical nanoparticles and nanoparticle compositions made thereby |
US9885001B2 (en) | 2014-09-23 | 2018-02-06 | Attostat, Inc. | Fuel additive composition and related methods |
US9883670B2 (en) * | 2014-09-23 | 2018-02-06 | Attostat, Inc. | Compositions and methods for treating plant diseases |
MA42161A (en) | 2014-10-14 | 2017-08-23 | Univ Chicago | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THEM |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
WO2016077769A1 (en) * | 2014-11-14 | 2016-05-19 | Massachusetts Institute Of Technology | Nanoparticles for magnetic particle imaging applications |
EP3223911B1 (en) * | 2014-12-19 | 2021-08-11 | Colgate-Palmolive Company | Stable whitening dentifrice composition with superior aesthetics |
US9839652B2 (en) | 2015-04-01 | 2017-12-12 | Attostat, Inc. | Nanoparticle compositions and methods for treating or preventing tissue infections and diseases |
KR101781976B1 (en) * | 2015-04-08 | 2017-10-23 | 한국과학기술연구원 | Nano-structured hybrid particle, manufacturing method thereof, and device containing the particle |
US11473202B2 (en) | 2015-04-13 | 2022-10-18 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
WO2016168346A1 (en) | 2015-04-13 | 2016-10-20 | Attostat, Inc. | Anti-corrosion nanoparticle compositions |
DE102015209594A1 (en) * | 2015-05-26 | 2016-12-01 | Siemens Aktiengesellschaft | Resistance covering for corona protection of an electrical machine |
US10201571B2 (en) | 2016-01-25 | 2019-02-12 | Attostat, Inc. | Nanoparticle compositions and methods for treating onychomychosis |
JP7090034B2 (en) | 2016-05-20 | 2022-06-23 | ザ ユニバーシティ オブ シカゴ | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy and any combination thereof |
IL254053B (en) | 2016-08-19 | 2021-03-25 | Univ Nat Taiwan | Hollow silica nanoparticles with encapsulated bioactive ingredients, preparation process and applications thereof |
WO2018069388A1 (en) * | 2016-10-11 | 2018-04-19 | Khalifa University of Science and Technology | Coated chloride salt particles and methods of making and using the same |
CN111194232B (en) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | Nanoscale metal-organic layer and metal-organic nanosheet |
EP3704723B1 (en) * | 2017-10-31 | 2023-10-11 | F. Hoffmann-La Roche AG | Improved magnetic particles and uses thereof |
DE102017010263A1 (en) * | 2017-11-07 | 2019-05-09 | Forschungszentrum Jülich GmbH | A method for producing hydrogenated amorphous silicon-containing composite colloids and for encapsulating substances with hydrogenated amorphous silicon-containing composite layers, and hydrogenated amorphous silicon-containing composite colloids and with silicon-containing composite layers encapsulated substances and their use |
US11646453B2 (en) | 2017-11-28 | 2023-05-09 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
US11018376B2 (en) | 2017-11-28 | 2021-05-25 | Attostat, Inc. | Nanoparticle compositions and methods for enhancing lead-acid batteries |
CN107973301A (en) * | 2017-12-12 | 2018-05-01 | 河北科技大学 | One kind is based on T-shaped microreactor controllable preparation Nano-meter SiO_22Method |
US10702843B2 (en) | 2018-03-29 | 2020-07-07 | Baker Hughes, A Ge Company, Llc | Compositions of matter comprising suspended nanoparticles and related methods |
CA3041931A1 (en) * | 2018-05-02 | 2019-11-02 | Royal Melbourne Institute Of Technology | A multimodal pet/mri contrast agent and a process for the synthesis thereof |
US11747341B2 (en) | 2019-03-04 | 2023-09-05 | Waters Technologies Corporation | Methods of use for low-bind polypropylene plates and vials |
KR20230097087A (en) | 2020-10-27 | 2023-06-30 | 일루시다 온콜로지, 인크. | Folate Receptor Targeting Nanoparticle Drug Conjugates and Uses Thereof |
CN112774683B (en) * | 2020-12-31 | 2022-05-24 | 中国环境科学研究院 | Carbon-based coated Ac-Fe/Co catalyst, and microemulsion preparation method and application thereof |
WO2024014179A1 (en) * | 2022-07-11 | 2024-01-18 | キヤノン電子管デバイス株式会社 | Rotating anode x-ray tube |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032471A (en) * | 1975-01-27 | 1977-06-28 | Eastman Kodak Company | Process for preparing yttrium oxide and rare earth metal oxide phosphors |
US4054465A (en) | 1976-09-29 | 1977-10-18 | Hercules Incorporated | Lead chromate pigments |
US4438156A (en) | 1982-09-30 | 1984-03-20 | International Business Machines Corporation | Mono-particle magnetic dispersion in organic polymers for magnetic recording |
US4661408A (en) * | 1986-03-18 | 1987-04-28 | E.I. Du Pont De Nemours And Company | Coated chromium dioxide particles |
FR2606419B1 (en) * | 1986-11-07 | 1994-04-01 | Commissariat A Energie Atomique | PROCESS FOR PRODUCING A FERROMAGNETIC COMPOSITION, FERROMAGNETIC LIQUID CRYSTAL OBTAINED BY THIS PROCESS AND DEVICE USING THE LIQUID CRYSTAL |
US5091206A (en) | 1987-10-26 | 1992-02-25 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
WO1993014022A1 (en) * | 1992-01-15 | 1993-07-22 | Battelle Memorial Institute | Process of forming metal compounds using reverse micelle or reverse microemulsion systems |
JPH0811691B2 (en) * | 1993-03-22 | 1996-02-07 | 工業技術院長 | Method for producing coprecipitated spherical fine particles containing yttrium / europium, coprecipitated sintered spherical fine particles and phosphor |
US6103379A (en) | 1994-10-06 | 2000-08-15 | Bar-Ilan University | Process for the preparation of microspheres and microspheres made thereby |
JPH08119631A (en) * | 1994-10-21 | 1996-05-14 | Shin Etsu Chem Co Ltd | Production of spherical oxide of rare earth element and its precursor |
US5695901A (en) | 1995-12-21 | 1997-12-09 | Colorado School Of Mines | Nano-size magnetic particles for reprographic processes and method of manufacturing the same |
US5637258A (en) * | 1996-03-18 | 1997-06-10 | Nanocrystals Technology L.P. | Method for producing rare earth activited metal oxide nanocrystals |
US5667716A (en) | 1996-07-01 | 1997-09-16 | Xerox Corporation | High magnetization aqueous ferrofluids and processes for preparation and use thereof |
US5874111A (en) | 1997-01-07 | 1999-02-23 | Maitra; Amarnath | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
US6344272B1 (en) * | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
WO1998051435A1 (en) * | 1997-05-14 | 1998-11-19 | Weixin Tang | Fully-coated, uniform-sized metallic particles |
US5879715A (en) | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
US5958329A (en) | 1997-11-06 | 1999-09-28 | United States Enrichment Corporation | Method and apparatus for producing nanoparticles at a high rate |
US5990479A (en) * | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
EP0972563A1 (en) * | 1998-07-15 | 2000-01-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates |
US6036886A (en) * | 1998-07-29 | 2000-03-14 | Nanocrystals Technology L.P. | Microemulsion method for producing activated metal oxide nanocrystals |
US6251303B1 (en) * | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
US6426513B1 (en) * | 1998-09-18 | 2002-07-30 | Massachusetts Institute Of Technology | Water-soluble thiol-capped nanocrystals |
US6326144B1 (en) * | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6306610B1 (en) * | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6548264B1 (en) | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
-
2000
- 2000-05-17 US US09/572,469 patent/US6548264B1/en not_active Expired - Fee Related
-
2001
- 2001-05-14 AT AT01935779T patent/ATE374946T1/en not_active IP Right Cessation
- 2001-05-14 CA CA2410023A patent/CA2410023C/en not_active Expired - Fee Related
- 2001-05-14 EP EP01935779A patent/EP1287359B1/en not_active Expired - Lifetime
- 2001-05-14 EP EP07112218A patent/EP1867993A1/en not_active Withdrawn
- 2001-05-14 AU AU2001261841A patent/AU2001261841B2/en not_active Ceased
- 2001-05-14 AU AU6184101A patent/AU6184101A/en active Pending
- 2001-05-14 WO PCT/US2001/040729 patent/WO2001088540A1/en active IP Right Grant
- 2001-05-14 JP JP2001584885A patent/JP2003533363A/en active Pending
- 2001-05-14 NZ NZ523078A patent/NZ523078A/en unknown
- 2001-05-14 DE DE60130757T patent/DE60130757T2/en not_active Expired - Lifetime
- 2001-11-13 US US10/010,807 patent/US6924116B2/en not_active Expired - Fee Related
-
2005
- 2005-07-25 US US11/188,459 patent/US7332351B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6924116B2 (en) | 2005-08-02 |
WO2001088540A1 (en) | 2001-11-22 |
US20060228554A1 (en) | 2006-10-12 |
NZ523078A (en) | 2004-09-24 |
CA2410023A1 (en) | 2001-11-22 |
US20020098529A1 (en) | 2002-07-25 |
US6548264B1 (en) | 2003-04-15 |
EP1287359A4 (en) | 2005-02-09 |
JP2003533363A (en) | 2003-11-11 |
AU2001261841B2 (en) | 2004-04-01 |
US7332351B2 (en) | 2008-02-19 |
ATE374946T1 (en) | 2007-10-15 |
AU6184101A (en) | 2001-11-26 |
DE60130757T2 (en) | 2008-07-17 |
DE60130757D1 (en) | 2007-11-15 |
EP1287359A1 (en) | 2003-03-05 |
EP1287359B1 (en) | 2007-10-03 |
EP1867993A1 (en) | 2007-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2410023C (en) | Coated nanoparticles | |
AU2001261841A1 (en) | Coated nanoparticles | |
Sonmez et al. | Synthesis and applications of Fe3O4/SiO2 core-shell materials | |
Philip | Magnetic nanofluids (Ferrofluids): Recent advances, applications, challenges, and future directions | |
Nam et al. | Nanoparticles: Synthesis and applications | |
Lu et al. | Colloidal nanoparticle clusters: functional materials by design | |
Jeong et al. | Superparamagnetic colloids: controlled synthesis and niche applications | |
US8512946B2 (en) | Composite particles | |
US7524630B2 (en) | Functionalized nanoparticles and methods of use | |
Xu et al. | Monodisperse magnetic nanoparticles for biomedical applications | |
Guerrero‐Martínez et al. | Recent progress on silica coating of nanoparticles and related nanomaterials | |
Ma et al. | Synthesis and surface modification of magnetic particles for application in biotechnology and biomedicine | |
JP2757964B2 (en) | Magnetic attractive particles and method for producing the same | |
Li et al. | Magnetic Fe3O4 nanoparticles: Synthesis and application in water treatment | |
US20060105170A1 (en) | Magnetic particle and process for preparation | |
Park et al. | Colloidally assembled zinc ferrite magnetic beads: superparamagnetic labels with high magnetic moments for MR sensors | |
Chen et al. | Preparation and characterization of magnetic nanoparticles and their silica egg-yolk-like nanostructures: a prospective multifunctional nanostructure platform | |
O'connor et al. | Nanophase magnetic materials: synthesis and properties | |
Miyajima et al. | Fabrication of porous FePt microcapsules for immunosensing techniques | |
Natarov et al. | Facile bulk preparation and structural characterization of agglomerated γ-Fe2O3/SiO2 nanocomposite particles for nucleic acids isolation and analysis | |
Büyüktiryaki et al. | Synthesis of Core-Shell Magnetic Nanoparticles | |
Pottail et al. | Magnetic synergism in Janus particles-Relevance to synthetic advances, materialistic properties and their niche applications | |
Warner et al. | Magnetic nanomaterials for environmental applications | |
Mohapatra et al. | Iron oxide and enzyme interface | |
Lee et al. | Development of magnetic luminescent core/shell nanocomplex particles with fluorescence using Rhodamine 6G |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |